Athanasios Dimopoulos

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1911858/publications.pdf

Version: 2024-02-01

1,028	66,657	1043 113	1220 227
papers	citations	h-index	g-index

1044	1044	1044	36653
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: <scp>IKEMA</scp> subgroup analysis. American Journal of Hematology, 2023, 98, .	2.0	6
2	Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review. Breast Care, 2022, 17, 63-70.	0.8	6
3	Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. Clinical and Experimental Medicine, 2022, 22, 319-323.	1.9	30
4	Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory WaldenstrÃ¶m's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study. Journal of Clinical Oncology, 2022, 40, 40-51.	0.8	22
5	Utilization and tolerance of beta-blockers among patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 31-37.	1.4	2
6	Myeloma patients with COVIDâ€19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine. British Journal of Haematology, 2022, 196, 356-359.	1.2	18
7	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomideâ€pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. European Journal of Haematology, 2022, 108, 73-83.	1.1	8
8	SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions. Science of the Total Environment, 2022, 804, 150151.	3.9	116
9	Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for WaldenstrÃ¶m's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. Journal of Clinical Oncology, 2022, 40, 52-62.	0.8	62
10	Lateâ€onset hematological complications post <scp>COVID</scp>â€19: An emerging medical problem for the hematologist. American Journal of Hematology, 2022, 97, 119-128.	2.0	36
11	Distinct neutralization profile of spike variants by antibodies induced upon <scp>SARSâ€CoV</scp>â€2 infection or vaccination. American Journal of Hematology, 2022, 97, E3.	2.0	12
12	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. Haematologica, 2022, 107, 1397-1409.	1.7	16
13	miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. British Journal of Cancer, 2022, 126, 79-90.	2.9	11
14	Kinetics of <scp>antiâ€SARSâ€CoV</scp>â€2 neutralizing antibodies development after <scp>BNT162b2</scp> vaccination in patients with amyloidosis and the impact of therapy. American Journal of Hematology, 2022, 97, E27.	2.0	5
15	Nonselective proteasome inhibitors in multiple myeloma and future perspectives. Expert Opinion on Pharmacotherapy, 2022, 23, 335-347.	0.9	4
16	Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies. Blood Advances, 2022, 6, 189-199.	2.5	10
17	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncology, The, 2022, 23, 65-76.	5.1	80
18	Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phaseï»¿ 2 trial. Blood Cancer Journal, 2022, 12, 9.	2.8	14

#	Article	IF	Citations
19	Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis. Biomedicines, 2022, 10, 204.	1.4	7
20	The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells. Biomedicines, 2022, 10, 209.	1.4	8
21	How I treat relapsed multiple myeloma. Blood, 2022, 139, 2904-2917.	0.6	16
22	Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy. Blood, 2022, 139, 1409-1412.	0.6	28
23	Managing hematological cancer patients during the COVID-19 pandemic: anÂESMO-EHA Interdisciplinary Expert Consensus. ESMO Open, 2022, 7, 100403.	2.0	32
24	Third dose of the <scp>BNT162b2</scp> vaccine results in very high levels of neutralizing antibodies against <scp>SARSâ€CoV</scp>â€2: Results of a prospective study in 150 health professionals in Greece. American Journal of Hematology, 2022, 97, .	2.0	10
25	Persisting Endothelial Cell Activation and Hypercoagulability after COVID-19 Recoveryâ€"The Prospective Observational ROADMAP-Post COVID-19 Study. Hemato, 2022, 3, 111-121.	0.2	4
26	Healthâ€related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone Â± subcutaneous daratumumab: Patientâ€reported outcomes from the APOLLO trial. American Journal of Hematology, 2022, 97, 481-490.	2.0	6
27	DUPLICATE: Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.2	0
28	Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 460-473.	0.2	13
29	Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. Biomedicines, 2022, 10, 338.	1.4	21
30	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncology, The, 2022, 23, 416-427.	5.1	54
31	Myocardial work and vascular dysfunction are partially improved at 12 months after <scp>COVID</scp>â€19 infection. European Journal of Heart Failure, 2022, 24, 727-729.	2.9	28
32	Future Developments in the Treatment of AL Amyloidosis. Hemato, 2022, 3, 131-152.	0.2	2
33	Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals. HemaSphere, 2022, 6, e677.	1.2	17
34	An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment. Therapeutic Advances in Hematology, 2022, 13, 204062072210884.	1.1	2
35	Molecular testing for prostate cancer in Greek patients.. Journal of Clinical Oncology, 2022, 40, 170-170.	0.8	0
36	Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical Study. Frontiers in Endocrinology, 2022, 13, 840668.	1.5	15

#	Article	IF	Citations
37	Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study. Hemato, 2022, 3, 188-203.	0.2	1
38	Diabetes and COVID-19; A Bidirectional Interplay. Frontiers in Endocrinology, 2022, 13, 780663.	1.5	38
39	Immune response and adverse events after vaccination against <scp>SARSâ€CoV</scp>â€2 in adult patients with transfusionâ€dependent thalassaemia. British Journal of Haematology, 2022, 197, 576-579.	1.2	6
40	Gender differences in COVID-19. Maturitas, 2022, 161, 72-73.	1.0	2
41	Post-protocol therapy and informative censoring in the CANDOR study â€“ Authors' reply. Lancet Oncology, The, 2022, 23, e98.	5.1	1
42	The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosis. Insights Into Imaging, 2022, 13, 55.	1.6	7
43	The COMPASS-COVID-19-ICU Study: Identification of Factors to Predict the Risk of Intubation and Mortality in Patients with Severe COVID-19. Hemato, 2022, 3, 204-218.	0.2	0
44	Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival. Frontiers in Oncology, 2022, 12, 847917.	1.3	12
45	Physical Exercise Restrains Cancer Progression through Muscle-Derived Factors. Cancers, 2022, 14, 1892.	1.7	12
46	Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple Myeloma. Radiology, 2022, 304, 137-144.	3.6	18
47	Characterizing Kinetics and Avidity of SARS-CoV-2 Antibody Responses in COVID-19 Greek Patients. Viruses, 2022, 14, 758.	1.5	4
48	Plasma Metabolomic Alterations Induced by COVID-19 Vaccination Reveal Putative Biomarkers Reflecting the Immune Response. Cells, 2022, 11, 1241.	1.8	14
49	Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience. Gynecologic Oncology Reports, 2022, 40, 100953.	0.3	1
50	â€œThe emerging role of capivasertib in breast cancerâ€. Breast, 2022, 63, 157-167.	0.9	20
51	Efficacy and tolerability of <scp>onceâ€weekly</scp> selinexor, bortezomib, and dexamethasone in comparison with standard <scp>twiceâ€weekly</scp> bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the <scp>BOSTON</scp> study. American Journal of Hematology, 2022, 97, .	2.0	7
52	Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends in Molecular Medicine, 2022, 28, 542-554.	3.5	104
53	Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma. In Vivo, 2022, 36, 1302-1315.	0.6	2
54	Immunogenic Cell Death, DAMPs and Prothymosin Î± as a Putative Anticancer Immune Response Biomarker. Cells, 2022, 11, 1415.	1.8	34

#	Article	IF	Citations
55	Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematology,the, 2022, 9, e403-e414.	2.2	23
56	Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma. Therapeutic Advances in Hematology, 2022, 13, 204062072210900.	1.1	8
57	Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies. Frontiers in Immunology, 2022, 13, .	2.2	8
58	Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients. Journal of Clinical Medicine, 2022, 11, 3088.	1.0	2
59	Advances in Gynecological Cancers. International Journal of Molecular Sciences, 2022, 23, 6152.	1.8	1
60	SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition. Cancers, 2022, 14, 2796.	1.7	9
61	Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study â€œREBUILDâ€. Cancers, 2022, 14, 2768.	1.7	6
62	Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for WaldenstrÃ¶m macroglobulinemia (WM): An international collaborative study.. Journal of Clinical Oncology, 2022, 40, 7566-7566.	0.8	9
63	Melflufen for the treatment of multiple myeloma. Expert Review of Clinical Pharmacology, 2022, 15, 371-382.	1.3	3
64	Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls. Journal of Clinical Medicine, 2022, 11, 3355.	1.0	4
65	Chromosome 1q21 aberrations identify ultra <scp>highâ€risk</scp> myeloma with prognostic and clinical implications. American Journal of Hematology, 2022, 97, 1142-1149.	2.0	10
66	Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. Nature Communications, 2022, 13, .	5.8	11
67	Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals. HemaSphere, 2022, 6, e747.	1.2	6
68	CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma.. Journal of Clinical Oncology, 2022, 40, TPS8070-TPS8070.	0.8	1
69	Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer. Clinical Breast Cancer, 2021, 21, e212-e219.	1.1	39
70	Next generation flow cytometry for MRD detection in patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 19-23.	1.4	22
71	Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 3-11.	1.4	18
72	Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. Blood, 2021, 137, 1154-1165.	0.6	49

#	Article	IF	Citations
73	Analytical methodologies for the detection of SARS-CoV-2 in wastewater: Protocols and future perspectives. TrAC - Trends in Analytical Chemistry, 2021, 134, 116125.	5.8	88
74	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncology, The, 2021, 22, 142-154.	5.1	46
75	Efficacy and safety of weekly carfilzomib (70â€‰mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. Leukemia and Lymphoma, 2021, 62, 358-367.	0.6	13
76	Emerging treatment strategies for COVID-19 infection. Clinical and Experimental Medicine, 2021, 21, 167-179.	1.9	232
77	Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia, 2021, 35, 1722-1731.	3.3	35
78	Daratumumabâ€based therapy for patients with monoclonal gammopathy of renal significance. British Journal of Haematology, 2021, 193, 113-118.	1.2	15
79	Screening for Gaucher disease among patients with plasma cell dyscrasias. Leukemia and Lymphoma, 2021, 62, 761-763.	0.6	2
80	COVID-19: time to flatten the infodemic curve. Clinical and Experimental Medicine, 2021, 21, 161-165.	1.9	27
81	Current and novel BTK inhibitors in WaldenstrÃ¶mâ€™s macroglobulinemia. Therapeutic Advances in Hematology, 2021, 12, 204062072198958.	1.1	11
82	Clinical perspectives of BET inhibition in ovarian cancer. Cellular Oncology (Dordrecht), 2021, 44, 237-249.	2.1	23
83	Cardiac amyloidosis presenting with coronary artery embolization. Reviews in Cardiovascular Medicine, 2021, 22, 883.	0.5	1
84	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. Journal of Biomedical Science, 2021, 28, 9.	2.6	167
85	SARS-CoV-2 Vaccines in Patients With Multiple Myeloma. HemaSphere, 2021, 5, e547.	1.2	31
86	Mutation-dependent treatment approaches for patients with complex multiple myeloma. Expert Review of Precision Medicine and Drug Development, 2021, 6, 189-201.	0.4	0
87	Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. Leukemia, 2021, 35, 1418-1427.	3.3	15
88	Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit. Cancers, 2021, 13, 763.	1.7	3
89	Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal Treatment and CDK 4/6 Inhibitors or Everolimus. Frontiers in Cardiovascular Medicine, 2021, 8, 638895.	1.1	6
90	Expert review on softâ€tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. British Journal of Haematology, 2021, 194, 496-507.	1.2	67

#	Article	IF	Citations
91	Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study. Cancers, 2021, 13, 1257.	1.7	9
92	SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. Vaccines, 2021, 9, 207.	2.1	12
93	Exercise-Induced Changes in Tumor Growth via Tumor Immunity. Sports, 2021, 9, 46.	0.7	7
94	Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays. Scientific Reports, 2021, 11, 6614.	1.6	33
95	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e119-e130.	5.1	92
96	Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. Microorganisms, 2021, 9, 546.	1.6	14
97	Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting. Current Oncology, 2021, 28, 1143-1152.	0.9	2
98	The relationship between cardiac injury, inflammation and coagulation in predicting COVID-19 outcome. Scientific Reports, 2021, 11, 6515.	1.6	11
99	Whole-Body Low-Dose CT in Multiple Myeloma: Diagnostic Value of Appendicular Medullary Patterns of Attenuation. American Journal of Roentgenology, 2021, 216, 742-751.	1.0	8
100	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e105-e118.	5.1	136
101	Cardiovascular toxicity of breast cancer treatment: an update. Cancer Chemotherapy and Pharmacology, 2021, 88, 15-24.	1.1	7
102	The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. Vaccines, 2021, 9, 422.	2.1	8
103	Trastuzumab administration during pregnancy: an update. BMC Cancer, 2021, 21, 463.	1.1	17
104	Healthâ€related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. British Journal of Haematology, 2021, 194, 132-139.	1.2	13
105	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. Journal of Hematology and Oncology, 2021, 14, 59.	6.9	11
106	A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis. Microorganisms, 2021, 9, 806.	1.6	12
107	European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. Haematologica, 2021, 106, 2054-2065.	1.7	27
108	Ageâ€dependent and genderâ€dependent antibody responses against <scp>SARSâ€CoV</scp>â€2 in health workers and octogenarians after vaccination with the <scp>BNT162b2 mRNA</scp> vaccine. American Journal of Hematology, 2021, 96, E257-E259.	2.0	138

#	Article	IF	Citations
109	Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood, 2021, 137, 3674-3676.	0.6	130
110	Nephrotoxicity in patients with cancer treated with immune checkpoint inhibitors.. Journal of Clinical Oncology, 2021, 39, e14558-e14558.	0.8	0
111	Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2021, 39, 8017-8017.	0.8	11
112	Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors. Journal of Hematology and Oncology, 2021, 14, 86.	6.9	31
113	Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients. Cancers, 2021, 13, 2452.	1.7	11
114	Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.. Journal of Clinical Oncology, 2021, 39, 8024-8024.	0.8	2
115	Germline mutations in a clinic-based series of pregnancy associated breast cancer patients. BMC Cancer, 2021, 21, 572.	1.1	9
116	Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.. Journal of Clinical Oncology, 2021, 39, 8019-8019.	0.8	2
117	Effect of age and frailty on the efficacy and tolerability of onceâ€weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. American Journal of Hematology, 2021, 96, 708-718.	2.0	16
118	A review of the impact of weather and climate variables to COVID-19: In the absence of public health measures high temperatures cannot probably mitigate outbreaks. Science of the Total Environment, 2021, 768, 144578.	3.9	59
119	Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.. Journal of Clinical Oncology, 2021, 39, 8020-8020.	0.8	2
120	The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. Thrombosis and Haemostasis, 2021, 121, 992-1007.	1.8	21
121	Molecular Epidemiology of SARS-CoV-2 in Greece Reveals Low Rates of Onward Virus Transmission after Lifting of Travel Restrictions Based on Risk Assessment during Summer 2020. MSphere, 2021, 6, e0018021.	1.3	8
122	Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. Oncologist, 2021, 26, 597-609.	1.9	15
123	Comparison of neutralizing antibody responses against <scp>SARSâ€CoV</scp>â€2 in healthy volunteers who received the <scp>BNT162b2 mRNA</scp> or the <scp>AZD1222</scp> vaccine: Should the second <scp>AZD1222</scp> vaccine dose be given earlier?. American Journal of Hematology, 2021, 96, E321-E324.	2.0	17
124	Management of patients with difficult-to-treat multiple myeloma. Future Oncology, 2021, 17, 2089-2105.	1.1	1
125	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet, The, 2021, 397, 2361-2371.	6.3	177
126	Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 361-367.	0.2	10

#	Article	IF	Citations
127	Real-World Treatment of Patients With Relapsed/Refractory Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 379-385.	0.2	11
128	CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience. Medical Sciences (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702 Td	1.3	0
129	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 801-812.	5.1	162
130	Managing complications secondary to WaldenstrÃ¶mâ€™s macroglobulinemia. Expert Review of Hematology, 2021, 14, 1-12.	1.0	0
131	A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. Cancers, 2021, 13, 3877.	1.7	12
132	Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. Journal of Infection, 2021, 83, 1-16.	1.7	127
133	High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. Vaccines, 2021, 9, 712.	2.1	25
134	Referral for â€œNeoadjuvant Chemotherapyâ€•for Muscle-Invasive Bladder Cancer to a Multidisciplinary Board: Patterns, Management and Outcomes. Cancer Management and Research, 2021, Volume 13, 5941-5955.	0.9	1
135	Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone. American Journal of Hematology, 2021, 96, E383-E386.	2.0	7
136	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Haematologica, 2021, 106, 2799-2812.	1.7	22
137	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. American Journal of Hematology, 2021, 96, 1120-1130.	2.0	15
138	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. New England Journal of Medicine, 2021, 385, 46-58.	13.9	268
139	Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. HemaSphere, 2021, 5, e614.	1.2	7
140	Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. Cells, 2021, 10, 1942.	1.8	38
141	SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors. European Journal of Internal Medicine, 2021, 89, 87-96.	1.0	53
142	ASSOCIATION OF -308G/A, -238G/A TNF-Î± POLYMORPHISMS WITH MULTIPLE MYELOMA RISK AND SURVIVAL: A SYSTEMATIC REVIEW AND META-ANALYSIS.. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	2
143	Ibrutinib plus rituximab for the treatment of adult patients with WaldenstrÃ¶mâ€™s macroglobulinemia: a safety evaluation. Expert Opinion on Drug Safety, 2021, 20, 987-995.	1.0	4
144	Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients. Cancers, 2021, 13, 4047.	1.7	8

#	Article	IF	Citations
145	MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment. Cancers, 2021, 13, 4114.	1.7	10
146	Paraneoplastic cerebellar degeneration in platinum-responsive endometrial cancer: A case report and review of literature. Gynecologic Oncology Reports, 2021, 37, 100826.	0.3	3
147	Systemic IL-15, IFN-Î³, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Reports, 2021, 36, 109504.	2.9	137
148	Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group. Journal of Clinical Medicine, 2021, 10, 3940.	1.0	10
149	Novel Nested-Seq Approach for SARS-CoV-2 Real-Time Epidemiology and In-Depth Mutational Profiling in Wastewater. International Journal of Molecular Sciences, 2021, 22, 8498.	1.8	11
150	Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naÃ¯ve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Medicine, 2021, 19, 208.	2.3	52
151	The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer Journal, 2021, 11, 138.	2.8	103
152	Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. Cancers, 2021, 13, 4480.	1.7	44
153	Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. Future Oncology, 2021, 17, 4797-4812.	1.1	6
154	Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study. Blood Advances, 2021, 5, 4398-4405.	2.5	39
155	Association of <scp>COVID</scp>â€19 with impaired endothelial glycocalyx, vascular function andÂmyocardial deformation 4 months after infection. European Journal of Heart Failure, 2021, 23, 1916-1926.	2.9	81
156	Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 259-266.	1.4	8
157	Early and late endocrine complications of COVID-19. Endocrine Connections, 2021, 10, R229-R239.	0.8	32
158	Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses. Journal of Clinical Medicine, 2021, 10, 4179.	1.0	10
159	Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma. Viruses, 2021, 13, 1844.	1.5	5
160	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 3613-3622.	0.8	25
161	Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: <scp>ICARIAâ€MM</scp> subgroup analysis. American Journal of Hematology, 2021, 96, E423-E427.	2.0	10
162	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. BMC Cancer, 2021, 21, 993.	1.1	8

#	Article	IF	Citations
163	Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. PLoS Pathogens, 2021, 17, e1009701.	2.1	12
164	Patterns of pharmaceuticals use during the first wave of COVID-19 pandemic in Athens, Greece as revealed by wastewater-based epidemiology. Science of the Total Environment, 2021, 798, 149014.	3.9	76
165	SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors. Breast, 2021, 60, 58-61.	0.9	15
166	Change in the chemical content of untreated wastewater of Athens, Greece under COVID-19 pandemic. Science of the Total Environment, 2021, 799, 149230.	3.9	61
167	Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review. Cancers, 2021, 13, 465.	1.7	7
168	Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. Leukemia, 2021, 35, 562-572.	3.3	43
169	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. HemaSphere, 2021, 5, e528.	1.2	45
170	Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. Viruses, 2021, 13, 26.	1.5	26
171	Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. Endocrine, 2021, 74, 478-497.	1.1	49
172	Elucidating Carfilzomibâ€™s Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin. International Journal of Molecular Sciences, 2021, 22, 10956.	1.8	8
173	Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers. Vaccines, 2021, 9, 1179.	2.1	7
174	Metabolic Disorders in Multiple Myeloma. International Journal of Molecular Sciences, 2021, 22, 11430.	1.8	16
175	Pembrolizumab in endometrial cancer: Where we stand now (Review). Oncology Letters, 2021, 22, 821.	0.8	10
176	Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals. Life, 2021, 11, 1077.	1.1	25
177	Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors. Vaccines, 2021, 9, 1148.	2.1	10
178	Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection. Frontiers in Immunology, 2021, 12, 746203.	2.2	10
179	Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study. Cancers, 2021, 13, 5057.	1.7	6
180	ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm. A Cohort Study by the Hellenic GU Cancer Group. Current Oncology, 2021, 28, 4474-4484.	0.9	1

#	Article	IF	Citations
181	BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients. Current Oncology, 2021, 28, 4446-4456.	0.9	2
182	Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis. Therapeutic Advances in Hematology, 2021, 12, 204062072110583.	1.1	5
183	Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. Blood, 2021, 138, 4202-4202.	0.6	0
184	Impact of Daratumumab-Containing Induction on Stem Cell Mobilization and Collection, Engraftment and Hospitalization Parameters Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. Blood, 2021, 138, 3886-3886.	0.6	5
185	Evaluation of Efficacy and Immune Modulation Associated with the Addition of IMiDs to Daratumumab Backbone in Patients Refractory to Both Drug Classes. Blood, 2021, 138, 1668-1668.	0.6	1
186	CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002. Blood, 2021, 138, 2731-2731.	0.6	18
187	Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients. Blood, 2021, 138, 153-153.	0.6	6
188	What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience. Current Oncology, 2021, 28, 4862-4873.	0.9	0
189	Prothymosin Î± and Its C-Terminal Immunoreactive Decapeptide Show no Evidence of Acute Toxicity: A Preliminary in Silico, in Vitro and in Vivo Investigation. Current Medicinal Chemistry, 2021, 28, .	1.2	1
190	Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd). Blood, 2021, 138, 1634-1634.	0.6	1
191	A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. Blood, 2021, 138, 2736-2736.	0.6	4
192	Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with WaldenstrÃ¶m's Macroglobulinemia with MYD88 and CXCR4 Mutations. Blood, 2021, 138, 1362-1362.	0.6	8
193	Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. Frontiers in Immunology, 2021, 12, 793953.	2.2	25
194	tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature. Biomedicines, 2021, 9, 1811.	1.4	8
195	The Mutational Landscape of Early-Onset Breast Cancer: A Next-Generation Sequencing Analysis. Frontiers in Oncology, 2021, 11, 797505.	1.3	4
196	Daratumumab for Immunoglobulin Light Chain Amyloidosis. Touch Reviews in Oncology & Haematology, 2021, 17, 79.	0.1	0
197	A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. International Journal of Molecular Sciences, 2021, 22, 13144.	1.8	13
198	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. Haematologica, 2020, 105, 468-477.	1.7	41

#	Article	IF	Citations
199	A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia, 2020, 34, 224-233.	3.3	122
200	A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica, 2020, 105, 201-208.	1.7	48
201	The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. Leukemia and Lymphoma, 2020, 61, 680-690.	0.6	9
202	A matching-adjusted indirect treatment comparison (MAIC) of daratumumabâ€“bortezomibâ€“melphalanâ€“prednisone (D-VMP) versus lenalidomideâ€“dexamethasone continuous (Rd continuous), lenalidomideâ€“dexamethasone 18 months (Rd 18), and melphalanâ€“prednisoneâ€“thalidomide (MPT). Leukemia and Lymphoma, 2020, 61, 714-720.	0.6	3
203	Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials. Leukemia and Lymphoma, 2020, 61, 37-46.	0.6	6
204	Multiple myeloma: Role of autologous transplantation. Cancer Treatment Reviews, 2020, 82, 101929.	3.4	42
205	Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 57-62.	0.2	10
206	Quality of life is maintained with ixazomib maintenance in postâ€transplant newly diagnosed multiple myeloma: The TOURMALINEâ€MM3 trial. European Journal of Haematology, 2020, 104, 443-458.	1.1	10
207	Consensus Statement on the Management of WaldenstrÃ¶m Macroglobulinemia Patients During the COVIDâ€19ÂPandemic. HemaSphere, 2020, 4, e433.	1.2	11
208	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. Journal of Clinical Oncology, 2020, 38, 4030-4041.	0.8	56
209	Consensus treatment recommendations from the tenth International Workshop for WaldenstrÃ¶m Macroglobulinaemia. Lancet Haematology,the, 2020, 7, e827-e837.	2.2	96
210	Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. Life, 2020, 10, 214.	1.1	31
211	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. Blood Cancer Journal, 2020, 10, 93.	2.8	13
212	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. Cancers, 2020, 12, 2864.	1.7	12
213	Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction. Journal of Clinical Medicine, 2020, 9, 3201.	1.0	1
214	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer Journal, 2020, 10, 102.	2.8	126
215	The Genomic Profile of Pregnancy-Associated Breast Cancer: A Systematic Review. Frontiers in Oncology, 2020, 10, 1773.	1.3	23
216	Cardiac arrest and drug-related cardiac toxicity in the Covid-19 era. Epidemiology, pathophysiology and management. Food and Chemical Toxicology, 2020, 145, 111742.	1.8	5

#	Article	IF	Citations
217	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet, The, 2020, 396, 186-197.	6.3	299
218	Clinical Perspectives of ERCC1 in Bladder Cancer. International Journal of Molecular Sciences, 2020, 21, 8829.	1.8	6
219	Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. Blood Advances, 2020, 4, 5449-5459.	2.5	17
220	Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 723-730.	0.6	22
221	Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19. Gynecologic Oncology Reports, 2020, 33, 100615.	0.3	7
222	Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma. Cancers, 2020, 12, 2006.	1.7	15
223	Organ-specific manifestations of COVID-19 infection. Clinical and Experimental Medicine, 2020, 20, 493-506.	1.9	351
224	Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. Journal of Clinical Oncology, 2020, 38, 3252-3260.	0.8	102
225	Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib. International Journal of Molecular Sciences, 2020, 21, 5185.	1.8	12
226	Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause. Leukemia and Lymphoma, 2020, 61, 3247-3250.	0.6	3
227	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic WaldenstrÃ¶m macroglobulinemia: the ASPEN study. Blood, 2020, 136, 2038-2050.	0.6	281
228	Response of an oncology unit in the midst of the COVID-19 outbreak. Journal of Oncology Pharmacy Practice, 2020, 26, 1947-1952.	0.5	1
229	Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19. Thrombosis and Haemostasis, 2020, 120, 1680-1690.	1.8	38
230	Emerging drugs for the treatment of WaldenstrÃ¶m macroglobulinemia. Expert Opinion on Emerging Drugs, 2020, 25, 433-444.	1.0	3
231	Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thrombosis and Haemostasis, 2020, 120, 1597-1628.	1.8	131
232	Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer Journal, 2020, 10, 91.	2.8	90
233	Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management. HemaSphere, 2020, 4, e454.	1.2	28
234	The emerging role of BET inhibitors in breast cancer. Breast, 2020, 53, 152-163.	0.9	31

#	Article	IF	Citations
235	Supportive medication in cancer during pregnancy. BMC Pregnancy and Childbirth, 2020, 20, 747.	0.9	3
236	Antiâ€“SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study. Microorganisms, 2020, 8, 1885.	1.6	39
237	Long-Term Neurodevelopmental Outcome of Children after in Utero Exposure to Chemotherapy. Cancers, 2020, 12, 3623.	1.7	10
238	A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Advances, 2020, 4, 5988-5999.	2.5	198
239	Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. Blood Cancer Journal, 2020, 10, 111.	2.8	13
240	Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients. Blood Cancer Journal, 2020, 10, 109.	2.8	21
241	Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma. Cancers, 2020, 12, 3245.	1.7	24
242	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet, The, 2020, 396, 1563-1573.	6.3	188
243	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVIDâ€19 pandemic. British Journal of Haematology, 2020, 190, 346-357.	1.2	17
244	Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanesâ€"a Hellenic Cooperative Oncology Group (HeCOG) Trial. British Journal of Cancer, 2020, 123, 355-361.	2.9	8
245	Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression. Cancer Treatment Reviews, 2020, 88, 102046.	3.4	39
246	Multiple myeloma: Current and future management in the aging population. Maturitas, 2020, 138, 8-13.	1.0	7
247	Long PFS of more than 7Âyears is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period. Annals of Hematology, 2020, 99, 1257-1264.	0.8	9
248	Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis. Leukemia and Lymphoma, 2020, 61, 2246-2249.	0.6	0
249	Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. Blood Cancer Journal, 2020, 10, 35.	2.8	16
250	Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. Expert Review of Hematology, 2020, 13, 421-433.	1.0	34
251	Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy. Gynecologic Oncology, 2020, 157, 599-605.	0.6	5
252	Efficacy of Panobinostat for the Treatment of Multiple Myeloma. Journal of Oncology, 2020, 2020, 1-11.	0.6	46

#	Article	IF	Citations
253	Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma. Blood Cancer Journal, 2020, 10, 25.	2.8	16
254	Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising? . Therapeutics and Clinical Risk Management, 2020, Volume 16, 141-146.	0.9	2
255	Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. Annals of Hematology, 2020, 99, 1793-1804.	0.8	4
256	A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e629-e644.	0.2	1
257	The current role of BTK inhibitors in the treatment of Waldenstromâ€™s Macroglobulinemia. Expert Review of Anticancer Therapy, 2020, 20, 663-674.	1.1	4
258	Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome. HemaSphere, 2020, 4, e381.	1.2	14
259	The Emerging Role of Convalescent Plasma in the Treatment of COVIDâ€19. HemaSphere, 2020, 4, e409.	1.2	42
260	Realâ€world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Grecoâ€Israeli collaborative myeloma working group. American Journal of Hematology, 2020, 95, 465-471.	2.0	9
261	Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. Rheumatology International, 2020, 40, 1353-1360.	1.5	33
262	Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e905-e909.	0.2	9
263	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia, 2020, 34, 2430-2440.	3.3	54
264	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2020, 10, 17.	2.8	75
265	Onceâ€weekly (70 mg/m²) vs twiceâ€weekly (56 mg/m²) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPIONâ€1 trials. Cancer Medicine, 2020, 9, 2989-2996.	1.3	16
266	Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 103-110.	1.4	11
267	Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 445-452.	0.2	23
268	Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy. Clinical Genitourinary Cancer, 2020, 18, e457-e472.	0.9	3
269	Autologous haematopoietic stem-cell transplantation versus bortezomibâ€“melphalanâ€“prednisone, with or without bortezomibâ€“lenalidomideâ€“dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematology,the, 2020, 7, e456-e468.	2.2	244
270	Cellâ€free <scp>DNA</scp> analysis for the detection of <scp>MYD88</scp> and <scp>CXCR4</scp> mutations in <scp>IgM</scp> monoclonal gammopathies; an update with clinicopathological correlations. American Journal of Hematology, 2020, 95, E148-E150.	2.0	12

#	Article	IF	Citations
271	Hematological findings and complications of <scp>COVID</scp>â€19. American Journal of Hematology, 2020, 95, 834-847.	2.0	1,354
272	Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Annals of Hematology, 2020, 99, 1049-1061.	0.8	31
273	Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. Leukemia and Lymphoma, 2020, 61, 1850-1859.	0.6	11
274	Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States. Expert Review of Hematology, 2020, 13, 687-696.	1.0	4
275	Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. Leukemia, 2020, 34, 3019-3027.	3.3	17
276	Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. Annals of Hematology, 2020, 99, 1251-1255.	0.8	17
277	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. Blood Cancer Journal, 2020, 10, 40.	2.8	15
278	Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood Advances, 2020, 4, 830-844.	2.5	54
279	Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia, 2020, 34, 1875-1884.	3.3	163
280	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia, 2020, 34, 2000-2011.	3.3	109
281	Significant reduction in the visits to the emergency room department during the COVID-19 pandemic in a tertiary hospital in Greece. Medicine (United States), 2020, 99, e23845.	0.4	20
282	Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory WaldenstrÃ¶m's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATETM Trial. Blood, 2020, 136, 38-39.	0.6	7
283	Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM Study. Blood, 2020, 136, 24-26.	0.6	19
284	Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 5-6.	0.6	41
285	Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study. Blood, 2020, 136, 35-36.	0.6	3
286	Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study. Blood, 2020, 136, 37-38.	0.6	16
287	DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 53-54.	0.6	13
288	Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study. Blood, 2020, 136, 4-6.	0.6	3

#	Article	IF	Citations
289	Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First - Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial. Blood, 2020, 136, 26-26.	0.6	13
290	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. Journal of Clinical Oncology, 2020, 38, 2380-2389.	0.8	110
291	Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88^{WT}) WaldenstrÃ¶m macroglobulinemia (WM).. Journal of Clinical Oncology, 2020, 38, e20056-e20056.	0.8	4
292	Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review. Annals of Translational Medicine, 2020, 8, 1603-1603.	0.7	8
293	The Prognostic Role of Protein Expression in Pregnancy Associated Breast Cancer: A Literature Review. Journal of Cancer Science and Clinical Therapeutics, 2020, 04, .	0.2	1
294	Oncology during the COVIDâ€'19 pandemic: challenges, dilemmas and the psychosocial impact on cancer patients (Review). Oncology Letters, 2020, 20, 441-447.	0.8	115
295	Pomalidomide, bortezomib, and dexamethasone (PVd) in lenalidomide (LEN)-pretreated relapsed refractory multiple myeloma: Subanalysis of patients with renal impairment in OPTIMISMM.. Journal of Clinical Oncology, 2020, 38, e20562-e20562.	0.8	2
296	Clinical biomarkers directing the management of patients with colon and lung cancer (beyond) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 46	0.1	2
297	IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure. Blood, 2020, 136, 12-12.	0.6	0
298	Progression-Free Survival (PFS) Benefit Demonstrated and Quality of Life (QoL) Maintained across Age and Frailty Subgroups with the Oral Proteasome Inhibitor (PI) Ixazomib Vs Placebo As Post-Induction Maintenance Therapy in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Analysis of the TOURMALINE-MM4 Phase 3 Trial. Blood, 2020, 136, 30-31.	0.6	6
299	A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias. Blood, 2020, 136, 8-8.	0.6	0
300	Carfilzomib-Induced Hypertension Is Mediated By Ion Channel Dysregulation in the Kidneys; The Potent Role of AMP-Activated Kinase Î±. Blood, 2020, 136, 34-35.	0.6	1
301	Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study. Blood, 2020, 136, 48-49.	0.6	7
302	Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment. Blood, 2020, 136, 25-25.	0.6	1
303	Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study. Blood, 2020, 136, 19-20.	0.6	0
304	Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study. Blood, 2020, 136, 29-29.	0.6	0
305	Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Renal Outcomes in AL Amyloidosis. Blood, 2020, 136, 33-33.	0.6	1
306	Derivation and Validation of a Predictive Score for Disease Worsening Inpatients with COVID-19. Blood, 2020, 136, 26-27.	0.6	0

#	Article	IF	Citations
307	The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents. Blood, 2020, 136, 21-21.	0.6	4
308	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. Blood, 2020, 136, 6-7.	0.6	0
309	Carfilzomib-Induced Cardiotoxicity in an In Vivo Model of Aging. Blood, 2020, 136, 18-18.	0.6	0
310	Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD+ Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Pts. Blood, 2020, 136, 20-21.	0.6	1
311	T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: Longitudinal Analysis during 7 Cycle Follow-up of the Rebuild Phase 2 Study. Blood, 2020, 136, 28-28.	0.6	1
312	Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone. Blood, 2020, 136, 39-41.	0.6	1
313	Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. Leukemia and Lymphoma, 2019, 60, 163-171.	0.6	11
314	Taxanes during pregnancy in cervical cancer: A systematic review and pooled analysis. Cancer Treatment Reviews, 2019, 79, 101885.	3.4	13
315	Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis. Circulation Research, 2019, 125, 744-758.	2.0	22
316	Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials. International Journal of Hematology, 2019, 110, 466-473.	0.7	12
317	Oral Selinexorâ€“Dexamethasone for Triple-Class Refractory Multiple Myeloma. New England Journal of Medicine, 2019, 381, 727-738.	13.9	460
318	Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?. Expert Review of Hematology, 2019, 12, 651-663.	1.0	12
319	Evaluating ibrutinib in the treatment of symptomatic Waldenstromâ€™s macroglobulinemia . Journal of Blood Medicine, 2019, Volume 10, 291-300.	0.7	13
320	Modelization of Blood-Borne Hypercoagulability in Myeloma: A Tissue-Factor-Bearing Microparticle-Driven Process. TH Open, 2019, 03, e340-e347.	0.7	6
321	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet, The, 2019, 394, 2096-2107.	6.3	435
322	Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma. Expert Review of Anticancer Therapy, 2019, 19, 921-928.	1.1	8
323	Nonâ€lethal proteasome inhibition activates proâ€tumorigenic pathways in multiple myeloma cells. Journal of Cellular and Molecular Medicine, 2019, 23, 8010-8018.	1.6	4
324	How I treat WaldenstrÃ¶m macroglobulinemia. Blood, 2019, 134, 2022-2035.	0.6	65

#	Article	IF	Citations
325	Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variant. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 52-53.	1.4	3
326	High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. Blood, 2019, 133, 1217-1221.	0.6	79
327	A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options. BMC Medical Genetics, 2019, 20, 23.	2.1	8
328	Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. Annals of Hematology, 2019, 98, 2139-2150.	0.8	39
329	Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 522-530.e1.	0.2	47
330	A revised international prognostic score system for WaldenstrÃ¶mâ€™s macroglobulinemia. Leukemia, 2019, 33, 2654-2661.	3.3	53
331	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 781-794.	5.1	254
332	Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study). Leukemia, 2019, 33, 2934-2946.	3.3	23
333	Progression Risk Stratification of Asymptomatic WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2019, 37, 1403-1411.	0.8	65
334	Discrepancies of current recommendations in breast cancer follow-up: a systematic review. Breast Cancer, 2019, 26, 681-686.	1.3	1
335	Meat, fish, dairy products and risk of hematological malignancies in adults â€“ a systematic review and meta-analysis of prospective studies. Leukemia and Lymphoma, 2019, 60, 1978-1990.	0.6	15
336	Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. Annals of Hematology, 2019, 98, 1427-1434.	0.8	9
337	Updates on thrombotic events associated with multiple myeloma. Expert Review of Hematology, 2019, 12, 355-365.	1.0	11
338	Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. European Journal of Haematology, 2019, 102, 494-503.	1.1	11
339	Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer Journal, 2019, 9, 23.	2.8	32
340	Anti-BCMA antibodies in the future management of multiple myeloma. Expert Review of Anticancer Therapy, 2019, 19, 319-326.	1.1	19
341	Systemic therapy in cervical cancer: 30 years in review. Critical Reviews in Oncology/Hematology, 2019, 137, 9-17.	2.0	119
342	The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG). Blood Cancer Journal, 2019, 9, 27.	2.8	53

#	Article	IF	Citations
343	Bone marrow biopsy in lowâ€risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. American Journal of Hematology, 2019, 94, E146-E149.	2.0	11
344	Insights on Multiple Myeloma Treatment Strategies. HemaSphere, 2019, 3, e163.	1.2	33
345	Myeloma bone disease: from biology findings to treatment approaches. Blood, 2019, 133, 1534-1539.	0.6	88
346	Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?. ESMO Open, 2019, 4, e000479.	2.0	8
347	Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma. Cancer Journal (Sudbury, Mass), 2019, 25, 2-10.	1.0	10
348	Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. HemaSphere, 2019, 3, e300.	1.2	20
349	Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. Blood Advances, 2019, 3, 4095-4103.	2.5	17
350	Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. Blood Advances, 2019, 3, 3002-3009.	2.5	37
351	Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide. Cancers, 2019, 11, 1764.	1.7	10
352	Treatment of Bingâ€“Neel syndrome with first line sequential chemoimmunotherapy. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10	0.4	8
353	Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 23-28.	0.2	2
354	Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. American Journal of Hematology, 2019, 94, 400-407.	2.0	21
355	Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. Blood, 2019, 133, 147-155.	0.6	33
356	Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood, 2019, 133, 710-723.	0.6	82
357	All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. European Journal of Cancer, 2019, 106, 89-98.	1.3	25
358	Phase 2 study of allâ€oral ixazomib, cyclophosphamide and lowâ€dose dexamethasone for relapsed/refractory multiple myeloma. British Journal of Haematology, 2019, 184, 536-546.	1.2	16
359	Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greeceâ€“â€“the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG). Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 491-501.	0.7	1
360	Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. International Journal of Cancer, 2019, 145, 559-568.	2.3	10

#	Article	IF	Citations
361	Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and metaâ€analysis of cohort studies. International Journal of Cancer, 2019, 145, 347-359.	2.3	36
362	Guillain-BarrÃ© Syndrome Related to Nivolumab: Case Report of a Patient With Urothelial Cancer and Review of the Literature. Clinical Genitourinary Cancer, 2019, 17, e360-e364.	0.9	9
363	Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. Leukemia and Lymphoma, 2019, 60, 619-628.	0.6	9
364	The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study. International Journal of Clinical Oncology, 2019, 24, 411-419.	1.0	4
365	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 393, 253-264.	6.3	187
366	Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom's Macroblobulinemia: Results of the Prospective Phase I/II HOVON 124/Ecwm-R2 Trial. Blood, 2019, 134, 344-344.	0.6	7
367	Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Renal Biomarker with Potential Clinical Applications in Monoclonal Gammopathy of Renal Significance (MGRS). Blood, 2019, 134, 3126-3126.	0.6	1
368	Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab Plus Pomalidomide and Dexamethasone: Icaria-MM Study. Blood, 2019, 134, 1850-1850.	0.6	6
369	Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas. Blood, 2019, 134, 3140-3140.	0.6	13
370	A Molecular Signature of Three tRNA-Derived RNA Fragments May Discriminate Smoldering from Symptomatic Multiple Myeloma Patients. Blood, 2019, 134, 5528-5528.	0.6	1
371	Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688). Blood, 2019, 134, LBA-6-LBA-6.	0.6	27
372	Bortezomib, lenalidomide, and dexamethasone (VRd) Â± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS).. Journal of Clinical Oncology, 2019, 37, TPS8055-TPS8055.	0.8	31
373	The extended 4-year follow-up results of the ELOQUENT-2 trial. Oncotarget, 2019, 10, 82-83.	0.8	10
374	Prognostic role of microRNAs in breast cancer: A systematic review. Oncotarget, 2019, 10, 7156-7178.	0.8	28
375	Clinical and biological implications of Hippo pathway dysregulation in sarcomas. Forum of Clinical Oncology, 2019, 9, 11-16.	0.1	1
376	Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment. Blood, 2019, 134, 1877-1877.	0.6	0
377	Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN). Blood, 2019, 134, 1868-1868.	0.6	1
378	Pulmonary Function Tests Reveal Unrecognized Lung Dysfunction and Have Independent Prognostic Significance in Patients with Systemic AL Amyloidosis. Blood, 2019, 134, 1842-1842.	0.6	0

#	Article	IF	Citations
379	Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis. Blood, 2019, 134, 1894-1894.	0.6	1
380	Alcohol consumption and risk of hematological malignancies: A metaâ€analysis of prospective studies. International Journal of Cancer, 2018, 143, 486-495.	2.3	36
381	How We Manage Patients with Plasmacytomas. Current Hematologic Malignancy Reports, 2018, 13, 227-235.	1.2	10
382	Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. Blood, 2018, 131, 1568-1575.	0.6	44
383	Denosumab for myeloma bone disease: ready for prime time?. Lancet Oncology, The, 2018, 19, 277-278.	5.1	3
384	Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer Journal, 2018, 8, 7.	2.8	219
385	Carfilzomib for relapsed or refractory multiple myeloma â€“ Authors' reply. Lancet Oncology, The, 2018, 19, e2.	5.1	2
386	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2018, 32, 1542-1560.	3.3	68
387	Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 431-437.	0.2	5
388	Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Blood Cancer Journal, 2018, 8, 31.	2.8	35
389	Consumption of fruits, vegetables, and risk of hematological malignancies: a systematic review and meta-analysis of prospective studies. Leukemia and Lymphoma, 2018, 59, 434-447.	0.6	23
390	Carfilzomibâ€“dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leukemia and Lymphoma, 2018, 59, 1364-1374.	0.6	6
391	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica, 2018, 103, 197-211.	1.7	110
392	Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. New England Journal of Medicine, 2018, 378, 518-528.	13.9	747
393	Rare manifestations of extramedullary myeloma: testicular plasmacytomas. Leukemia and Lymphoma, 2018, 59, 2002-2004.	0.6	6
394	The role of ibrutinib in WaldenstrÃ¶m macroglobulinemia. Expert Opinion on Orphan Drugs, 2018, 6, 85-89.	0.5	0
395	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood, 2018, 131, 301-310.	0.6	216
396	The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. Blood, 2018, 131, 464-467.	0.6	54

#	Article	IF	Citations
397	Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or) Tj ETQq1 1 0.784314 rgBT /Ove 2018, 59, 983-987.	0.6	4
398	Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. Journal of Clinical Oncology, 2018, 36, 2035-2043.	0.8	55
399	Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology, 2018, 36, 728-734.	0.8	221
400	Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 234-241.	1.4	24
401	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer Journal, 2018, 8, 109.	2.8	170
402	Thalidomide for myeloma: still here?. Lancet Haematology,the, 2018, 5, e439-e440.	2.2	1
403	Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. Blood Cancer Journal, 2018, 8, 102.	2.8	23
404	Ibrutinib and Rituximab in WaldenstrÃ¶mâ€™s Macroglobulinemia. New England Journal of Medicine, 2018, 379, 1973-1976.	13.9	7
405	Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2018, 379, 1811-1822.	13.9	413
406	Management of uterine sarcomas and prognostic indicators: real world data from a single-institution. BMC Cancer, 2018, 18, 1247.	1.1	29
407	Cardio-oncology: A Focus on Cardiotoxicity. European Cardiology Review, 2018, 13, 64.	0.7	65
408	Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. Blood Cancer Journal, 2018, 8, 95.	2.8	59
409	Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica, 2018, 103, 2088-2096.	1.7	187
410	Management of multiple myeloma bone disease: impact of treatment on renal function. Expert Review of Hematology, 2018, 11, 881-888.	1.0	10
411	Prognostic factors for multiple myeloma in the era of novel therapies. Expert Review of Hematology, 2018, 11, 863-879.	1.0	28
412	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4â€year followâ€up and analysis of relative progressionâ€free survival from the randomized ELOQUENTâ€2 trial. Cancer, 2018, 124, 4032-4043.	2.0	118
413	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica, 2018, 103, 1772-1784.	1.7	86
414	Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S249-S250.	0.2	6

#	Article	IF	Citations
415	A predictive model for risk of early gradeâ€‰â‰¥â€‰3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Leukemia, 2018, 32, 1404-1413.	3.3	53
416	Optimizing therapy in bortezomib-exposed patients with multiple myeloma. Expert Review of Hematology, 2018, 11, 463-469.	1.0	1
417	Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer Journal, 2018, 8, 46.	2.8	39
418	Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncology, The, 2018, 19, 953-964.	5.1	169
419	Phase 3 Trial of Ibrutinib plus Rituximab in WaldenstrÃ¶mâ€™s Macroglobulinemia. New England Journal of Medicine, 2018, 378, 2399-2410.	13.9	291
420	Treatment and outcome patterns in European patients with WaldenstrÃ¶m's macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematology,the, 2018, 5, e299-e309.	2.2	41
421	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e401-e419.	0.2	61
422	Managing myeloma with limited resources in the era of novel drugs. Leukemia and Lymphoma, 2018, 59, 2269-2270.	0.6	2
423	Proteasome Inhibitors in WaldenstrÃ¶m Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 829-840.	0.9	11
424	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia, 2018, 32, 1883-1898.	3.3	81
425	Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. Leukemia, 2018, 32, 2617-2625.	3.3	40
426	Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. Journal of Hematology and Oncology, 2018, 11, 49.	6.9	33
427	Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. Blood Cancer Journal, 2018, 8, 42.	2.8	29
428	Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Annals of Translational Medicine, 2018, 6, 144-144.	0.7	19
429	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia, 2018, 32, 1697-1712.	3.3	83
430	One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone. Blood, 2018, 132, 156-156.	0.6	20
431	Ibrutinib Treatment in WaldenstrÃ¶m's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATETM Study. Blood, 2018, 132, 149-149.	0.6	20
432	Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial. Blood, 2018, 132, 301-301.	0.6	9

#	Article	IF	Citations
433	Subgroup Analysis of Patients with Biochemical or Symptomatic Relapse at the Time of Enrollment in the Endeavor Study. Blood, 2018, 132, 3243-3243.	0.6	14
434	Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients. Blood, 2018, 132, 1966-1966.	0.6	3
435	Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines. Blood, 2018, 132, 3244-3244.	0.6	1
436	Pomalidomide (POM), bortezomib, and lowâ€dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.. Journal of Clinical Oncology, 2018, 36, 8001-8001.	0.8	15
437	Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2018, 36, 8040-8040.	0.8	10
438	Evaluation of the effect of CXCL13 mRNA expression in early breast cancer outcome: A confirmatory study.. Journal of Clinical Oncology, 2018, 36, e24286-e24286.	0.8	2
439	A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2018, 36, TPS8056-TPS8056.	0.8	2
440	Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).. Journal of Clinical Oncology, 2018, 36, TPS8059-TPS8059.	0.8	8
441	Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA.. Journal of Clinical Oncology, 2018, 36, TPS8062-TPS8062.	0.8	8
442	How I treat elderly patients with plasma cell dyscrasias. Aging, 2018, 10, 4248-4268.	1.4	9
443	Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent. Oncotarget, 2018, 9, 17797-17809.	0.8	10
444	Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study. Oncotarget, 2018, 9, 36906-36913.	0.8	7
445	How I treat rituximab refractory patients with WM. Oncotarget, 2018, 9, 36824-36825.	0.8	6
446	Treating ALK-positive non-small cell lung cancer. Annals of Translational Medicine, 2018, 6, 141-141.	0.7	23
447	Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?. Annals of Translational Medicine, 2018, 6, 143-143.	0.7	13
448	Ibrutinib for rituximab-refractory WaldenstrÃ¶m macro-globulinemia. Oncotarget, 2018, 9, 12536-12537.	0.8	1
449	Time to deterioration (TTD) in health-related quality of life (HRQoL) with carfilzomib plus dexamethasone (Kd56) versus bortezomib plus dexamethasone (Vd) in the ENDEAVOR trial.. Journal of Clinical Oncology, 2018, 36, e20011-e20011.	0.8	0
450	Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in WaldenstrÃ¶m's macroglobulinemia.. Journal of Clinical Oncology, 2018, 36, 8003-8003.	0.8	0

#	Article	IF	Citations
451	IMiDs for myeloma induced renal impairment. Oncotarget, 2018, 9, 35476-35477.	0.8	4
452	Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials. Blood, 2018, 132, 1963-1963.	0.6	9
453	Carfilzomib Induces Acute Endothelial Dysfunction Which Correlates with the Occurrence of Cardiovascular Events. Blood, 2018, 132, 3247-3247.	0.6	0
454	A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation. Leukemia and Lymphoma, 2017, 58, 153-161.	0.6	29
455	Emerging treatment approaches for myeloma-related bone disease. Expert Review of Hematology, 2017, 10, 217-228.	1.0	13
456	Efficacy and safety of elotuzumab for the treatment of multiple myeloma. Expert Opinion on Drug Safety, 2017, 16, 1-9.	1.0	4
457	Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer. Hellenic Journal of Cardiology, 2017, 58, 215-219.	0.4	17
458	Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. British Journal of Haematology, 2017, 177, 404-413.	1.2	58
459	Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. British Journal of Haematology, 2017, 177, 441-448.	1.2	21
460	Investigation and management of IgM and WaldenstrÃ¶mâ€associated peripheral neuropathies: recommendations from the <scp>IWWM</scp>â€8 consensus panel. British Journal of Haematology, 2017, 176, 728-742.	1.2	58
461	Prognosis and risk assessment in AL amyloidosis - There and back again. British Journal of Haematology, 2017, 177, 343-345.	1.2	1
462	Diagnostic work-up and specific causes of acute kidney injury. Intensive Care Medicine, 2017, 43, 829-840.	3.9	44
463	When to recommend a second autograft in patients with relapsed myeloma?. Leukemia and Lymphoma, 2017, 58, 781-787.	0.6	4
464	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus lowâ€dose dexamethasone: A pooled analysis. European Journal of Haematology, 2017, 99, 199-206.	1.1	21
465	Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation. Oncologist, 2017, 22, 667-679.	1.9	62
466	Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. Leukemia and Lymphoma, 2017, 58, 2304-2309.	0.6	17
467	Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. American Journal of Hematology, 2017, 92, 632-639.	2.0	48
468	Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Leukemia and Lymphoma, 2017, 58, 2501-2504.	0.6	22

#	Article	IF	Citations
469	Population Pharmacokinetics and Exposureâ€“Response Relationship of Carfilzomib in Patients With Multiple Myeloma. Journal of Clinical Pharmacology, 2017, 57, 663-677.	1.0	10
470	Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. Haematologica, 2017, 102, 593-599.	1.7	72
471	Ibrutinib for patients with rituximab-refractory WaldenstrÃ¶m's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncology, The, 2017, 18, 241-250.	5.1	212
472	Current treatment options and investigational drugs for Waldenstromâ€™s Macroglobulinemia. Expert Opinion on Investigational Drugs, 2017, 26, 197-205.	1.9	12
473	Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. Leukemia and Lymphoma, 2017, 58, 1832-1839.	0.6	24
474	BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood, 2017, 129, 456-459.	0.6	62
475	Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica, 2017, 102, 43-51.	1.7	112
476	Gefitinib: an â€œorphanâ€•drug for non-small cell lung cancer. Expert Opinion on Orphan Drugs, 2017, 5, 899-906.	0.5	2
477	Daratumumab combinations: what can we learn?. Blood, 2017, 130, 957-958.	0.6	3
478	Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 1327-1337.	5.1	320
479	Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <scp>ELOQUENT</scp>â€2 followâ€up and postâ€hoc analyses on progressionâ€free survival and tumour growth. British Journal of Haematology, 2017, 178, 896-905.	1.2	120
480	Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. European Journal of Haematology, 2017, 99, 409-414.	1.1	37
481	Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM). Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e26-e27.	0.2	27
482	Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma. Annals of Hematology, 2017, 96, 1707-1714.	0.8	7
483	An overview of the role of carfilzomib in the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy, 2017, 18, 1883-1897.	0.9	23
484	Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the <scp>PANORAMA</scp> 1 trial. British Journal of Haematology, 2017, 179, 66-74.	1.2	16
485	Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory WaldenstrÃ¶mâ€™s macroglobulinemia. Leukemia and Lymphoma, 2017, 58, 1506-1508.	0.6	9
486	Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma. Radiology, 2017, 282, 484-493.	3.6	81

#	Article	IF	Citations
487	Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome. Hematological Oncology, 2017, 35, 734-740.	0.8	6
488	Treatment Recommendations in WaldenstrÃ¶m Macroglobulinemia. , 2017, , 367-370.		1
489	Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events. Scientific Reports, 2017, 7, 17802.	1.6	17
490	Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Advances, 2017, 1, 449-454.	2.5	89
491	Disease control should be the goal of therapy for WM patients. Blood Advances, 2017, 1, 2483-2485.	2.5	5
492	Brain Oscillations Elicited by the Cold Pressor Test: A Putative Index of Untreated Essential Hypertension. International Journal of Hypertension, 2017, 2017, 1-17.	0.5	6
493	Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function. Clinical Pharmacology: Advances and Applications, 2017, Volume 9, 133-145.	0.8	10
494	Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial. Blood, 2017, 130, 743-743.	0.6	16
495	Genomic Predictors of Progression-Free Survival Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Carfilzomib and Dexamethasone or Bortezomib and Dexamethasone in the Phase 3 Endeavor Trial. Blood, 2017, 130, 839-839.	0.6	4
496	The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e407-e417.	1.8	41
497	Evidence of a Redox-Dependent Regulation of Immune Responses to Exercise-Induced Inflammation. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-19.	1.9	22
498	Recent advances in the management of <scp>AL</scp> Amyloidosis. British Journal of Haematology, 2016, 172, 170-186.	1.2	88
499	Bortezomibâ€based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. American Journal of Hematology, 2016, 91, 499-502.	2.0	73
500	Proteasome inhibitor associated thrombotic microangiopathy. American Journal of Hematology, 2016, 91, E348-52.	2.0	95
501	Treatment of relapsed urothelial bladder cancer with vinflunine. Anti-Cancer Drugs, 2016, 27, 48-53.	0.7	19
502	Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study. Clinical Colorectal Cancer, 2016, 15, e133-e140.	1.0	46
503	A review of the venous thrombotic issues associated with multiple myeloma. Expert Review of Hematology, 2016, 9, 695-706.	1.0	21
504	Carfilozomib versus bortezomib for relapsed or refractory myeloma â€“ Authors' reply. Lancet Oncology, The, 2016, 17, e126.	5.1	4

#	Article	IF	Citations
505	Emerging antibodies for the treatment of multiple myeloma. Expert Opinion on Emerging Drugs, 2016, 21, 225-237.	1.0	25
506	Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 335-340.	0.2	16
507	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. Drugs, 2016, 76, 853-867.	4.9	34
508	Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS). Leukemia and Lymphoma, 2016, 57, 2839-2847.	0.6	9
509	DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7. Blood, 2016, 128, 1214-1225.	0.6	29
510	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood, 2016, 128, 497-503.	0.6	144
511	Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. Blood, 2016, 128, 405-409.	0.6	37
512	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood, 2016, 128, 1174-1180.	0.6	110
513	Treatment recommendations from the Eighth International Workshop on WaldenstrÃ¶mâ€™s Macroglobulinemia. Blood, 2016, 128, 1321-1328.	0.6	161
514	Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. Journal of Clinical Oncology, 2016, 34, 3921-3930.	0.8	70
515	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood, 2016, 127, 713-721.	0.6	121
516	Current therapy guidelines for Waldenstrom's macroglobulinaemia. Best Practice and Research in Clinical Haematology, 2016, 29, 194-205.	0.7	5
517	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2016, 375, 1319-1331.	13.9	1,210
518	Outcome of patients with nonmetastatic muscleâ€invasive bladder cancer not undergoing cystectomy after treatment with noncisplatinâ€based chemotherapy and/or radiotherapy: a retrospective analysis. Cancer Medicine, 2016, 5, 1098-1107.	1.3	6
519	<scp>TLR</scp>4/<scp>TIRAP</scp> polymorphisms are associated with progression and survival of patients with symptomatic myeloma. British Journal of Haematology, 2016, 172, 44-47.	1.2	8
520	Recent Data Supporting Novel Management Strategies for Patients With Multiple Myeloma. JAMA Oncology, 2016, 2, 1261.	3.4	1
521	Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica, 2016, 101, 872-878.	1.7	19
522	Current treatments for renal failure due to multiple myeloma. Expert Opinion on Pharmacotherapy, 2016, 17, 2165-2177.	0.9	28

#	Article	IF	Citations
523	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346.	5.1	1,866
524	Managing renal complications in multiple myeloma. Expert Review of Hematology, 2016, 9, 839-850.	1.0	14
525	Recommendations for the diagnosis and initial evaluation of patients with WaldenstrÃ¶m Macroglobulinaemia: A Task Force from the 8th International Workshop on WaldenstrÃ¶m Macroglobulinaemia. British Journal of Haematology, 2016, 175, 77-86.	1.2	61
526	Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematology,the, 2016, 3, e506-e515.	2.2	121
527	Carfilzomib for treating myeloma. Expert Opinion on Orphan Drugs, 2016, 4, 989-999.	0.5	2
528	Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. Journal of Clinical Oncology, 2016, 34, 3609-3617.	0.8	71
529	Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG). Clinical Genitourinary Cancer, 2016, 14, e153-e159.	0.9	8
530	Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. Leukemia and Lymphoma, 2016, 57, 2833-2838.	0.6	27
531	Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG). World Journal of Urology, 2016, 34, 853-857.	1.2	5
532	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncology, The, 2016, 17, 27-38.	5.1	723
533	VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 329-334.e1.	0.2	26
534	Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haematologica, 2016, 101, 363-370.	1.7	33
535	The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. Oncologist, 2016, 21, 333-342.	1.9	28
536	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. Journal of Clinical Oncology, 2016, 34, 1544-1557.	0.8	294
537	Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma. Leukemia and Lymphoma, 2016, 57, 1776-1780.	0.6	3
538	Primary failure of bortezomib in newly diagnosed multiple myeloma â€“ understanding the magnitude, predictors, and significance. Leukemia and Lymphoma, 2016, 57, 1382-1388.	0.6	10
539	Neutrophil Gelatinaseâ€“Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 29-35.	0.2	16
540	Expression of Î±5-integrin, Î±7-integrin, Î•-cadherin, and N-cadherin in localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 165.e11-165.e18.	0.8	22

#	Article	IF	Citations
541	The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies. Cancer Treatment Reviews, 2016, 43, 58-66.	3.4	51
542	Final Analysis of Overall Survival from the First Trial. Blood, 2016, 128, 241-241.	0.6	11
543	Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with WaldenstrÃ¶M's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years. Blood, 2016, 128, 2957-2957.	0.6	1
544	Health Related Quality of Life Results from the Open-Label, Randomized, Phase III Endeavor Trial Evaluating Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2016, 128, 3309-3309.	0.6	8
545	Pomalidomide with Low Dose Dexamethasone Is Effective Irrespective of Primary or Secondary Resistance to Lenalidomide but the IMiD-Free Interval Is Important. Blood, 2016, 128, 3310-3310.	0.6	1
546	Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with Multiple Myeloma Who Have Received 1 or More Prior Lines of Therapy. Blood, 2016, 128, 3340-3340.	0.6	1
547	Findings of Whole Body Computed Tomography Compared to Conventional Skeletal Survey in Patients with Monoclonal Plasma Cell Disorders - a Study of the International Myeloma Working Group. Blood, 2016, 128, 4468-4468.	0.6	11
548	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. Blood, 2016, 128, 646-646.	0.6	37
549	Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial). Blood, 2016, 128, 673-673.	0.6	29
550	Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial).. Journal of Clinical Oncology, 2016, 34, 8000-8000.	0.8	52
551	The Development of an Angiogenic Protein â€œSignatureâ€•in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling. PLoS ONE, 2016, 11, e0156403.	1.1	22
552	The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e407-e417.	1.8	31
553	DNA damage, tumor mutational load and their impact on immune responses against cancer. Annals of Translational Medicine, 2016, 4, 264-264.	0.7	35
554	Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsy. Clinical Nephrology, 2016, 85 (2016), 44-54.	0.4	7
555	Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials.. Journal of Clinical Oncology, 2016, 34, 8031-8031.	0.8	0
556	Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study Group. Blood, 2016, 128, 4488-4488.	0.6	0
557	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. Blood, 2016, 128, 4414-4414.	0.6	0
558	European Post-Approval Safety Study (PASS) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including SPM, in a Large Cohort of Patients Treated with Lenalidomide, Thalidomide, and Bortezomib. Blood, 2016, 128, 3331-3331.	0.6	0

#	Article	IF	Citations
559	Indirubins: A Potential Therapeutic Target in Multiple Myeloma. Blood, 2016, 128, 3259-3259.	0.6	0
560	Real-World Data on Clinical Characteristics, Prognosis and Outcome of Primary Plasma Cell Leukemia: A Study of the Greek Myeloma Study Group in the Era of Novel Agents. Blood, 2016, 128, 4490-4490.	0.6	0
561	Safety Results of a Phase 2 Multicenter, Open-Label Study of Pomalidomide (CC-4047) Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment. Blood, 2016, 128, 3311-3311.	0.6	0
562	Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients with AL Amyloidosis Treated with Bortezomib. Blood, 2016, 128, 4500-4500.	0.6	0
563	Chromatin Histone Modifying and DNA Repair Inhibition Enhances the Anti-Myeloma Activity of Melphalan. Blood, 2016, 128, 4437-4437.	0.6	0
564	Longâ€term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. American Journal of Hematology, 2015, 90, E60-5.	2.0	55
565	Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point. Haematologica, 2015, 100, e328-30.	1.7	28
566	Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica, 2015, 100, 100-106.	1.7	33
567	Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma. Haematologica, 2015, 100, e63-e67.	1.7	22
568	Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. Haematologica, 2015, 100, e446-e449.	1.7	44
569	Treatment options for relapsed and refractory multiple myeloma. Blood, 2015, 125, 3085-3099.	0.6	136
570	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood, 2015, 125, 2068-2074.	0.6	586
571	Dexamethasone, rituximab, and cyclophosphamide as primary treatment of WaldenstrÃ¶m macroglobulinemia: final analysis of a phase 2 study. Blood, 2015, 126, 1392-1394.	0.6	108
572	Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?. OncoTargets and Therapy, 2015, 8, 1843.	1.0	5
573	Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer. PLoS ONE, 2015, 10, e0117654.	1.1	33
574	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 2015, 373, 621-631.	13.9	1,139
575	Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 519-530.	0.2	40
576	Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica, 2015, 100, 1327-1333.	1.7	68

#	Article	IF	Citations
577	Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomibâ€melphalanâ€prednisone in the phase III VISTA study. American Journal of Hematology, 2015, 90, 314-319.	2.0	58
578	Alcohol intake, alcoholic beverage type and multiple myeloma risk: a meta-analysis of 26 observational studies. Leukemia and Lymphoma, 2015, 56, 1484-1501.	0.6	13
579	Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement. Journal of Clinical Oncology, 2015, 33, 657-664.	0.8	330
580	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of Clinical Oncology, 2015, 33, 2863-2869.	0.8	1,525
581	Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Expert Review of Anticancer Therapy, 2015, 15, 737-748.	1.1	48
582	An update on the use of lenalidomide for the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy, 2015, 16, 1865-1877.	0.9	9
583	Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. Leukemia and Lymphoma, 2015, 56, 1723-1726.	0.6	19
584	Fulvestrant and male breast cancer: a pooled analysis. Breast Cancer Research and Treatment, 2015, 149, 269-275.	1.1	34
585	Reply to D.L. Cooper. Journal of Clinical Oncology, 2015, 33, 2926-2927.	0.8	0
586	Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. Haematologica, 2015, 100, 1334-1339.	1.7	44
587	Appraising myc involvement in high risk myeloma. Leukemia and Lymphoma, 2015, 56, 551-552.	0.6	4
588	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. Haematologica, 2015, 100, 1254-1266.	1.7	289
589	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, BloodÂand Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 2039-2051.	2.0	146
590	Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. Annals of Hematology, 2015, 94, 2033-2042.	0.8	43
591	Clinical characteristics of patients with relapsed multiple myeloma. Cancer Treatment Reviews, 2015, 41, 827-835.	3.4	30
592	Risk Factors for Multiple Myeloma: A Systematic Review of Meta-Analyses. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 563-577.e3.	0.2	50
593	Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2015, 33, 3459-3466.	0.8	138
594	Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Supportive Care in Cancer, 2015, 23, 2045-2051.	1.0	25

#	Article	IF	Citations
595	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. New England Journal of Medicine, 2015, 372, 142-152.	13.9	1,144
596	Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the <scp>MM</scp>â€003 trial for pomalidomide plus lowâ€dose dexamethasone. British Journal of Haematology, 2015, 168, 820-823.	1.2	21
597	Current treatment landscape for relapsed and/or refractory multiple myeloma. Nature Reviews Clinical Oncology, 2015, 12, 42-54.	12.5	175
598	A phase 2, randomized, doubleâ€blind, placeboâ€controlled study of siltuximab (antiâ€IL6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. American Journal of Hematology, 2015, 90, 42-49.	2.0	116
599	Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup. Blood, 2015, 126, 1844-1844.	0.6	5
600	Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070). Blood, 2015, 126, 26-26.	0.6	16
601	Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up. Blood, 2015, 126, 28-28.	0.6	22
602	Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866). Blood, 2015, 126, 30-30.	0.6	8
603	Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment. Blood, 2015, 126, 3031-3031.	0.6	3
604	The State of Chromatin Condensation, the Expression of Genes Involved in DNA Damage Response and the DNA Repair Capacity Affect the Drug Sensitivity of PBMCs of Myeloma Patients Treated with Melphalan. Blood, 2015, 126, 3628-3628.	0.6	2
605	Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on Dialysis. Blood, 2015, 126, 374-374.	0.6	6
606	Diffusion-Weighted Imaging Improves Accuracy in the Diagnosis of MRI Patterns of Marrow Involvement in Newly Diagnosed Myeloma: Results of a Prospective Study in 99 Patients. Blood, 2015, 126, 4178-4178.	0.6	12
607	Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study. Blood, 2015, 126, 4201-4201.	0.6	3
608	An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2015, 126, 4225-4225.	0.6	3
609	A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial. Blood, 2015, 126, 4239-4239.	0.6	13
610	Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866). Blood, 2015, 126, 4250-4250.	0.6	27
611	Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial. Blood, 2015, 126, 730-730.	0.6	15
612	Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391). Blood, 2015, 126, 731-731.	0.6	8

#	Article	IF	Citations
613	Global Myeloma Research Clusters, Output, and Citations: A Bibliometric Mapping and Clustering Analysis. PLoS ONE, 2015, 10, e0116966.	1.1	10
614	Pomalidomide â€“ An Appraisal of Its Clinical Development and Role in the Treatment of Relapsed/Refractory Multiple Myeloma. European Oncology and Haematology, 2015, 11, 109.	0.0	0
615	Bevacizumab (BEV) with or after chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (PROC): Exploratory analyses of the AURELIA trial.. Journal of Clinical Oncology, 2015, 33, 5551-5551.	0.8	0
616	The patient with myeloma. , 2015, , 1276-1291.		0
617	The Simultaneous Accumulation of the Extremely Cytotoxic Interstrand Cross-Links and Double-Strand Breaks Contributes to the Successful Anti-Myeloma Therapy; The Effect of DNA Repair Inhibitors. Blood, 2015, 126, 4177-4177.	0.6	0
618	Analysis of Patient (Pt) Outcomes By Prior Treatment and Depth of Response in Stratus (MM-010), a Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2015, 126, 1834-1834.	0.6	0
619	Bortezomib-Based Triplets Are Associated with a High Probability of Dialysis Independence and Rapid Renal Recovery in Newly Diagnosed Myeloma Patients with Severe Renal Failure or Those Requiring Dialysis. Blood, 2015, 126, 1832-1832.	0.6	0
620	Analysis of Molecular-Cellular Responses to Proteasome Inhibitors in Multiple Myeloma Patients; A Translational Approach of Proteasome Inhibitors In Vivo Effects from the Drosophila Experimental Model to Humans. Blood, 2015, 126, 3250-3250.	0.6	0
621	Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma. Blood, 2015, 126, 3045-3045.	0.6	0
622	Prospective Evaluation of Blood Pressure Monitoring and Baroreceptor Reflex Sensitivity (BRS) in Patients with AL Amyloidosis: Prognostic and Pathophysiologic Implications. Blood, 2015, 126, 3054-3054.	0.6	0
623	Validation of the Novel Criteria for the Definition of Symptomatic Myeloma: A Single Center Experience in 216 Patients with the Previous Diagnosis of Asymptomatic Disease. Blood, 2015, 126, 4251-4251.	0.6	0
624	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. Blood, 2015, 126, 4188-4188.	0.6	1
625	Real-World Prospective Evaluation of Different Geriatric Assessment Tools in Unselected Elderly Patients with Symptomatic Myeloma. Blood, 2015, 126, 4242-4242.	0.6	0
626	Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer. OncoTargets and Therapy, 2014, 7, 1837.	1.0	7
627	Conservative Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients. International Journal of Dentistry, 2014, 2014, 1-7.	0.5	20
628	Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. Leukemia and Lymphoma, 2014, 55, 2018-2023.	0.6	57
629	Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged â‰¥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. Leukemia and Lymphoma, 2014, 55, 1489-1497.	0.6	37
630	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica, 2014, 99, 232-242.	1.7	185

#	Article	IF	Citations
631	Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. European Journal of Haematology, 2014, 92, 308-312.	1.1	31
632	Treatment with bortezomibâ€based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group. American Journal of Hematology, 2014, 89, 145-150.	2.0	56
633	The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma. BMC Cancer, 2014, 14, 149.	1.1	18
634	Association of VEGF-A Splice Variant mRNA Expression With Outcome in Bevacizumab-Treated Patients With Metastatic Breast Cancer. Clinical Breast Cancer, 2014, 14, 330-338.	1.1	10
635	Staging and prognostication of multiple myeloma. Expert Review of Hematology, 2014, 7, 21-31.	1.0	33
636	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncology, The, 2014, 15, 333-342.	5.1	256
637	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis, 2014, 35, 1012-1019.	1.3	145
638	The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2014, 55, 11-18.	0.6	4
639	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. Journal of Clinical Oncology, 2014, 32, 587-600.	0.8	330
640	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology, The, 2014, 15, e538-e548.	5.1	3,343
641	Hematologic Response and Stabilization of Renal Function in a Patient With Light Chain Deposition Disease After Lenalidomide Treatment: A Novel Therapeutic Approach?. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e179-e181.	0.2	7
642	The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group. American Journal of Hematology, 2014, 89, 34-40.	2.0	33
643	Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients. American Journal of Hematology, 2014, 89, 803-808.	2.0	54
644	European Perspective on Multiple Myeloma Treatment Strategies in 2014. Oncologist, 2014, 19, 829-844.	1.9	90
645	Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. New England Journal of Medicine, 2014, 371, 906-917.	13.9	697
646	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncology, The, 2014, 15, 1195-1206.	5.1	695
647	Prognostic Significance of Cytoreductive Nephrectomy in Patients With Synchronous Metastases From Renal Cell Carcinoma Treated With First-Line Sunitinib: A European Multiinstitutional Study. Clinical Genitourinary Cancer, 2014, 12, 373-383.	0.9	39
648	Less strength and more fractures for MGUS bones. Blood, 2014, 123, 603-604.	0.6	2

#	Article	IF	Citations
649	Treatment recommendations for patients with WaldenstrÃ¶m macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood, 2014, 124, 1404-1411.	0.6	138
650	Solitary bone plasmacytomas need to flow. Blood, 2014, 124, 1209-1210.	0.6	6
651	Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes. Blood, 2014, 124, 306-306.	0.6	4
652	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. Blood, 2014, 124, 35-35.	0.6	11
653	Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy. Blood, 2014, 124, 4738-4738.	0.6	3
654	Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study. Blood, 2014, 124, 4742-4742.	0.6	3
655	Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment. Blood, 2014, 124, 4769-4769.	0.6	1
656	Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study. Blood, 2014, 124, 79-79.	0.6	15
657	Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): Overall survival (OS) results of MM-003 after adjustment for crossover.. Journal of Clinical Oncology, 2014, 32, 8593-8593.	0.8	1
658	The STRATUS trial (MM-010): A single-arm phase 3b study of pomalidomide plus low-dose dexamethasone (POM + LoDEX) in refractory or relapsed and refractory multiple myeloma.. Journal of Clinical Oncology, 2014, 32, TPS8625-TPS8625.	0.8	2
659	Circulating Levels of Angiogenic Cytokines in Waldenstromâ€™s Macroglobulinemia: Clinical Correlations. Current Angiogenesis, 2014, 2, 104-109.	0.1	0
660	Platinum-based therapy and oral cyclophosphamide as salvage therapy in heavily pretreated metastatic castrate resistant prostate cancer (mCRPC) patients with poor performance status and bulky/LN/visceral disease.. Journal of Clinical Oncology, 2014, 32, e16096-e16096.	0.8	0
661	Risk of Progression and Survival in Newly Diagnosed Multiple Myeloma Patients Non-Responsive to Bortezomib-Based Induction Therapy: an Observational Multicenter International Study. Blood, 2014, 124, 3488-3488.	0.6	0
662	Elevated Involved Light Chains Discordant to the Increase of the Involved Heavy Chains Identifies a Subset of Multiple Myeloma Patients with Worse Outcome. Blood, 2014, 124, 2132-2132.	0.6	0
663	High Bone Turnover Is Present in Patients with Primary Systemic (AL) Amyloidosis and Increased Osteoprotegerin Identifies Patients with Poor Survival within Mayo Stage 1 Disease. Blood, 2014, 124, 2028-2028.	0.6	0
664	Hemodynamic, Functional and Structural Markers of Vascular Involvement in Primary Systemic Light Chain (AL) Amyloidosis. Blood, 2014, 124, 2029-2029.	0.6	0
665	The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma. Blood, 2014, 124, 3462-3462.	0.6	0
666	Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Is Able to Distinguish Diffuse from Normal MRI Pattern of Marrow Involvement in Patients with Multiple Myeloma. Blood, 2014, 124, 3461-3461.	0.6	1

#	Article	IF	Citations
667	Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents. Blood, 2014, 124, 3464-3464.	0.6	0
668	Renal Outcomes in Patients with AL Amyloidosis: Evaluation of Prognostic Factors and Impact of Therapy with Novel Agents. Blood, 2014, 124, 2130-2130.	0.6	0
669	Genetic Factors Related with Early Onset of Osteonecrosis of the Jaw in Patients with Multiple Myeloma Under Zoledronic Acid Therapy. Blood, 2014, 124, 2115-2115.	0.6	0
670	Impact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial Results. Blood, 2014, 124, 2112-2112.	0.6	1
671	Translating Findings of Proteasome Inhibitors Effects from the in VivoDrosophila Experimental Model to Humans: The Paradigm of the Molecular-Cellular Responses to Bortezomib and Carfilzomib. Blood, 2014, 124, 4814-4814.	0.6	0
672	Circulating Adamts-13 Is Reduced in Patients with Waldenstrom's Macroglobulinemia and Is Associated with Increased IgM Levels and Features of the Disease but Not with the Increased Levels of Von Willebrand Factor. Blood, 2014, 124, 5741-5741.	0.6	0
673	Plasmablastic lymphoma of the breast in an immunocompetent patient: long-lasting complete response induced by chemotherapy and autologous stem cell trasplantation. Anticancer Research, 2014, 34, 5111-5.	0.5	6
674	Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group. Anticancer Research, 2014, 34, 5649-55.	0.5	8
675	Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. BMC Cancer, 2013, 13, 163.	1.1	27
676	Metachronous appearance of second malignancies in medullary thyroid carcinoma (MTC) patients: a diagnostic challenge and brief review of the literature. Endocrine, 2013, 44, 610-615.	1.1	3
677	How lenalidomide is changing the treatment of patients with multiple myeloma. Critical Reviews in Oncology/Hematology, 2013, 88, S23-S35.	2.0	24
678	Proteasome Inhibitor Therapy for WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 235-237.	0.2	6
679	Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leukemia Research, 2013, 37, 829-837.	0.4	48
680	International Myeloma Working Group Recommendations for the Treatment of Multiple Myelomaâ€“Related Bone Disease. Journal of Clinical Oncology, 2013, 31, 2347-2357.	0.8	307
681	Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer. International Journal of Molecular Sciences, 2013, 14, 15885-15909.	1.8	105
682	Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2013, 14, 1055-1066.	5.1	710
683	Proteasome dysfunction inDrosophilasignals to an Nrf2-dependent regulatory circuit aiming to restore proteostasis and prevent premature aging. Aging Cell, 2013, 12, 802-813.	3.0	98
684	Current treatments for renal failure due to multiple myeloma. Expert Opinion on Pharmacotherapy, 2013, 14, 1477-1495.	0.9	27

#	Article	IF	Citations
685	Primary therapy of WaldenstrÃ¶m macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood, 2013, 122, 3276-3282.	0.6	180
686	Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood, 2013, 121, 318-328.	0.6	112
687	WaldenstrÃ¶mâ€™s Macroglobulinemia. , 2013, , 681-699.		0
688	Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	5.1	219
689	A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. British Journal of Haematology, 2013, 160, 649-659.	1.2	111
690	Reâ€evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents. Hematological Oncology, 2013, 31, 96-102.	0.8	55
691	Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica, 2013, 98, 784-788.	1.7	57
692	Improved Survival Trends in Platinum-Resistant Patients with Advanced Ovarian, Fallopian or Peritoneal Cancer Treated with First-Line Paclitaxel/Platinum Chemotherapy: The Impact of Novel Agents. Oncology, 2013, 84, 158-165.	0.9	16
693	Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica, 2013, 98, 1264-1272.	1.7	35
694	Ambulatory blood pressure monitoring in acute stroke. Blood Pressure Monitoring, 2013, 18, 94-100.	0.4	15
695	Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases. PLoS ONE, 2013, 8, e58182.	1.1	27
696	Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. OncoTargets and Therapy, 2013, 6, 531.	1.0	30
697	Reply to S. Girnius et al. Journal of Clinical Oncology, 2013, 31, 2750-2751.	0.8	1
698	Tobacco smoking and risk of multiple myeloma: A metaâ€analysis of 40 observational studies. International Journal of Cancer, 2013, 132, 2413-2431.	2.3	23
699	Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomideâ€based regimens. American Journal of Hematology, 2013, 88, 765-770.	2.0	40
700	The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC. European Journal of Haematology, 2013, 91, n/a-n/a.	1.1	37
701	Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma. Journal of Clinical Oncology, 2013, 31, 448-455.	0.8	250
702	Optimal use of bisphosphonates in patients with multiple myeloma. Blood, 2013, 121, 3325-3328.	0.6	37

#	Article	IF	Citations
703	A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood, 2013, 121, 3420-3427.	0.6	385
704	Elevated Von Willebrand Factor Antigen Serum Levels Are Associated With Poor Prognosis In Patients With Symptomatic Waldenstromâ€™s Macroglobulinemia. Blood, 2013, 122, 1860-1860.	0.6	2
705	Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) Improves Health-Related Quality Of Life (HRQoL) Vs High-Dose Dexamethasone (HiDEX) In Relapsed Refractory Multiple Myeloma (RRMM) Patients Enrolled In MM-003 Phase 3 Randomized Trial. Blood, 2013, 122, 2939-2939.	0.6	2
706	MM-003 Phase 3 Study Of Pomalidomide In Combination With Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM): POM + Lodex Is Beneficial For Elderly Patients (> 65 Years of Age). Blood, 2013, 122, 3198-3198.	0.6	2
707	Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2013, 122, 408-408.	0.6	10
708	Patient Outcomes By Prior Therapies and Depth Of Response: Analysis Of MM-003, a Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2013, 122, 686-686.	0.6	2
709	MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2013, 31, 8510-8510.	0.8	2
710	Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI).. Journal of Clinical Oncology, 2013, 31, 8527-8527.	0.8	7
711	Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003.. Journal of Clinical Oncology, 2013, 31, 8583-8583.	0.8	1
712	Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma. Medical Science Monitor, 2013, 19, 1188-1194.	0.5	7
713	Prognostic Significance of ESR1 Gene Amplification, mRNA/Protein Expression and Functional Profiles in High-Risk Early Breast Cancer: A Translational Study of the Hellenic Cooperative Oncology Group (HeCOG). PLoS ONE, 2013, 8, e70634.	1.1	15
714	Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003.. Journal of Clinical Oncology, 2013, 31, 8528-8528.	0.8	0
715	Estimated Glomerular Filtration Rate Calculated By The CKD-EPI Formula Has Improved Prognostic Ability Over MDRD Formula In Patients With Newly Diagnosed, Symptomatic, Multiple Myeloma: Analysis In 1937 Patients. Blood, 2013, 122, 1867-1867.	0.6	1
716	Disease-Associated Changes In The Repair Efficiency Of Double Strand Breaks Affect Melphalan Sensitivity Of The Bone Marrow Plasma Cells and Correlate With The Clinical Outcome Of Anti-Myeloma Therapy. Blood, 2013, 122, 3723-3723.	0.6	4
717	Genetic Variations In TLR-4/TIRAP Genes Influence Response To IMiDs-Based Regimens and Conventional Chemotherapy In Patients With Multiple Myeloma. Blood, 2013, 122, 1861-1861.	0.6	0
718	Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). Blood, 2013, 122, 3185-3185.	0.6	0
719	Non-secretory myeloma: one, two, or more entities?. Oncology, 2013, 27, 930-2.	0.4	7
720	Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care. Oncologist, 2012, 17, 239-249.	1.9	105

#	Article	IF	Citations
721	European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses. Oncologist, 2012, 17, 592-606.	1.9	48
722	Replication Protein A in Nonearly Ovarian Adenocarcinomas. International Journal of Gynecological Pathology, 2012, 31, 319-327.	0.9	16
723	Ambulatory blood pressure monitoring in acute stroke. Blood Pressure Monitoring, 2012, 17, 220-221.	0.4	2
724	Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment. Clinical Cancer Research, 2012, 18, 2145-2163.	3.2	38
725	Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer. Journal of Clinical Oncology, 2012, 30, 3841-3847.	0.8	110
726	A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood, 2012, 119, 2764-2767.	0.6	143
727	When a little aspirin may be enough. Blood, 2012, 119, 905-906.	0.6	5
728	A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood, 2012, 119, 5384-5390.	0.6	88
729	VWF, WM, and angiogenesis: is there a link?. Blood, 2012, 120, 3163-3164.	0.6	2
730	New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. Journal of Clinical Oncology, 2012, 30, 4541-4549.	0.8	735
731	Sclerostin: a possible target for the management of cancer-induced bone disease. Expert Opinion on Therapeutic Targets, 2012, 16, 761-769.	1.5	30
732	Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients â‰¥65Âyears old with relapsed or refractory multiple myeloma. International Journal of Hematology, 2012, 96, 254-262.	0.7	21
733	Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer. International Journal of Cardiology, 2012, 154, 341-344.	0.8	4
734	Development and validation of a PCRâ€based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs. British Journal of Clinical Pharmacology, 2012, 74, 842-853.	1.1	10
735	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia, 2012, 26, 149-157.	3.3	664
736	How to Manage Neutropenia in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 5-11.	0.2	40
737	Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment. Cancer Treatment Reviews, 2012, 38, 1012-1019.	3.4	16
738	Evolving Chemotherapy Options for the Treatment of Myeloma Kidney: A 40-Year Perspective. Advances in Chronic Kidney Disease, 2012, 19, 312-323.	0.6	2

#	Article	IF	Citations
739	Prevention and Treatment of Myeloma Bone Disease. Current Hematologic Malignancy Reports, 2012, 7, 249-257.	1.2	11
740	New Insights in WaldenstrÃ¶mâ€™s Macroglobulinemia. , 2012, , 223-236.		0
741	Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel. PLoS ONE, 2012, 7, e37946.	1.1	54
742	Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome. Haematologica, 2012, 97, 1699-1703.	1.7	30
743	Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction postâ€bortezomib monotherapy. International Journal of Cancer, 2012, 131, 1466-1471.	2.3	150
744	Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents. American Journal of Hematology, 2012, 87, 734-736.	2.0	8
745	Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients. American Journal of Hematology, 2012, 87, 861-864.	2.0	81
746	Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma. New England Journal of Medicine, 2012, 366, 1759-1769.	13.9	692
747	Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. Medical Oncology, 2012, 29, 750-754.	1.2	10
748	Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Research and Treatment, 2012, 132, 609-619.	1.1	48
749	Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era. European Journal of Haematology, 2012, 89, 10-15.	1.1	28
750	Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: Report of 2 cases with clinical implications. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2012, 113, 234-238.	0.2	60
751	Circulating angiopoietinâ€1 to angiopoietinâ€2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. International Journal of Cancer, 2012, 130, 735-742.	2.3	32
752	VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. International Journal of Cancer, 2012, 130, 857-864.	2.3	134
753	Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study. Blood, 2012, 120, LBA-6-LBA-6.	0.6	14
754	Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology, 2012, 30, 8018-8018.	0.8	13
755	WaldenstrÃ¶mâ€™s Macroglobulinemia Associated with Cryoglobulinemia: Pathogenetic, Clinical, and Therapeutic Aspects. , 2012, , 277-283.		0
756	Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood, 2011, 117, 4701-4705.	0.6	377

#	Article	IF	Citations
757	Advances in Imaging and the Management of Myeloma Bone Disease. Journal of Clinical Oncology, 2011, 29, 1907-1915.	0.8	110
758	Emerging drugs for WaldenstrÃ¶m's macroglobulinemia. Expert Opinion on Emerging Drugs, 2011, 16, 45-57.	1.0	5
759	Increased Serum Lactate Dehydrongenase Should Be Included Among the Variables That Define Very-High-Risk Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 409-413.	0.2	39
760	Adjusting for Patient Crossover in Clinical Trials Using External Data: A Case Study of Lenalidomide for Advanced Multiple Myeloma. Value in Health, 2011, 14, 672-678.	0.1	9
761	Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 38-43.	0.2	59
762	Prognostication of the High-Risk WM Patient. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 127-129.	0.2	1
763	Management of advanced bladder cancer in patients with impaired renal function. Expert Review of Anticancer Therapy, 2011, 11, 931-939.	1.1	8
764	Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treatment Reviews, 2011, 37, 266-283.	3.4	66
765	Intermittent Docetaxel Chemotherapy in Patients With Castrate-resistant Prostate Cancer. Urology, 2011, 77, 682-687.	0.5	22
766	Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): A risk adapted protocol of the Hellenic Cooperative Oncology Group. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 189-193.	0.8	12
767	Advances in the treatment of multiple myeloma. European Journal of Cancer, 2011, 47, S306-S308.	1.3	3
768	Zoledronic acid for all patients with newly diagnosed multiple myeloma?. Lancet Oncology, The, 2011, 12, 711-712.	5.1	0
769	The Mediterranean Diet in Cancer Prevention: A Review. Journal of Medicinal Food, 2011, 14, 1065-1078.	0.8	82
770	Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: The impact of inflammatory process and oxidative stress. Atherosclerosis, 2011, 214, 151-157.	0.4	63
771	The role of the cell adhesion molecules (integrins / cadherins) in prostate cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2011, 37, 302-306.	0.7	14
772	Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and WaldenstrÃ¶m macroglobulinemia. Blood, 2011, 117, 2918-2923.	0.6	37
773	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood, 2011, 117, 4691-4695.	0.6	849
774	Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood, 2011, 117, 4696-4700.	0.6	285

#	Article	IF	Citations
775	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood, 2011, 117, 6063-6073.	0.6	282
776	Bortezomib for AL amyloidosis: moving forward. Blood, 2011, 118, 827-828.	0.6	20
777	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood, 2011, 118, 4519-4529.	0.6	309
778	CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Haematologica, 2011, 96, 1557-1559.	1.7	31
779	Characterization of haematological parameters with bortezomibâ€“melphalanâ€“prednisone versus melphalanâ€“prednisone in newly diagnosed myeloma, with evaluation of longâ€term outcomes and risk of thromboembolic events with use of erythropoiesisâ€stimulating agents: analysis of the VISTA trial. British Journal of Haematology, 2011, 153, 212-221.	1.2	13
780	Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. European Journal of Haematology, 2011, 86, 23-31.	1.1	126
781	Emerging therapies for the treatment of relapsed or refractory multiple myeloma. European Journal of Haematology, 2011, 86, 1-15.	1.1	70
782	Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalanâ€“prednisone vs. melphalanâ€“prednisone in the phase III VISTA trial in multiple myeloma. European Journal of Haematology, 2011, 86, 372-384.	1.1	77
783	Short progressionâ€free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agentâ€based therapy. European Journal of Haematology, 2011, 87, 323-329.	1.1	8
784	The repair of melphalan-induced DNA adducts in the transcribed strand of active genes is subject to a strong polarity effect. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011, 714, 78-87.	0.4	8
785	Response to bortezomib of a patient with scleromyxedema refractory to other therapies. Leukemia Research, 2011, 35, e209-e211.	0.4	27
786	Consensus on the utility of bone markers in the malignant bone disease setting. Critical Reviews in Oncology/Hematology, 2011, 80, 411-432.	2.0	84
787	Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications. Cancer Immunology, Immunotherapy, 2011, 60, 305-317.	2.0	26
788	Olive oil intake is inversely related to cancer prevalence: a systematic review and a meta-analysis of 13800 patients and 23340 controls in 19 observational studies. Lipids in Health and Disease, 2011, 10, 127.	1.2	213
789	A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study. BMC Medicine, 2011, 9, 10.	2.3	41
790	Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. Critical Reviews in Oncology/Hematology, 2011, 77, S13-S23.	2.0	23
791	No significant improvement in the outcome of patients with WaldenstrÃ¶m's macroglobulinemia treated over the last 25 years. American Journal of Hematology, 2011, 86, 479-483.	2.0	43
792	Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias. American Journal of Hematology, 2011, 86, 882-884.	2.0	16

#	Article	IF	Citations
793	Outcomes after adjuvant chemotherapy in the treatment of highâ€risk urothelial carcinoma of the upper urinary tract (UUTâ€UC). Cancer, 2011, 117, 5500-5508.	2.0	106
794	Relapse of Ovarian Cancer With Bone Marrow Infiltration and Concurrent Emergence of Therapy-Related Acute Myeloid Leukemia: A Case Report. Journal of Clinical Oncology, 2011, 29, e295-e296.	0.8	2
795	Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective. Oncologist, 2011, 16, 388-403.	1.9	26
796	Leukocytoclastic Vasculitis after Long-Term Treatment with Sunitinib: A Case Report. Case Reports in Oncology, 2011, 4, 385-391.	0.3	10
797	Reply to C.A. Hutchison et al. Journal of Clinical Oncology, 2011, 29, e314-e314.	0.8	2
798	A Risk-Adapted Strategy of Adjuvant Paclitaxel/Carboplatin in Early-Stage Ovarian Cancer: Time-Dependent Effect of 4 versus 6 Cycles on Outcome. Oncology, 2011, 81, 365-371.	0.9	1
799	Thyroid hormone and recovery of cardiac function in patients with acute myocardial infarction: a strong association?. European Journal of Endocrinology, 2011, 165, 107-114.	1.9	77
800	Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica, 2010, 95, 1738-1744.	1.7	109
801	Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood, 2010, 116, 3743-3750.	0.6	101
802	Prechemotherapy Serum Levels of CD105, Transforming Growth Factor Î²2, and Vascular Endothelial Growth Factor Are Associated With Prognosis in Patients With Advanced Epithelial Ovarian Cancer Treated With Cytoreductive Surgery and Platinum-Based Chemotherapy. International Journal of Gynecological Cancer, 2010, 20, 248-254.	1.2	9
803	Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial. Journal of Clinical Oncology, 2010, 28, 2259-2266.	0.8	403
804	Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model. BMC Cancer, 2010, 10, 45.	1.1	27
805	Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. European Journal of Haematology, 2010, 85, 1-5.	1.1	28
806	High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. European Journal of Haematology, 2010, 85, 114-119.	1.1	113
807	The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer, 2010, 116, 3807-3814.	2.0	118
808	Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stemâ€cell transplantation: Results of a single institution, randomized phase 2 trial. American Journal of Hematology, 2010, 85, 863-867.	2.0	44
809	High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leukemia Research, 2010, 34, 399-402.	0.4	26
810	Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. Leukemia Research, 2010, 34, 1111-1118.	0.4	55

#	Article	IF	Citations
811	Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leukemia Research, 2010, 34, 1340-1343.	0.4	56
812	Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leukemia Research, 2010, 34, 1395-1397.	0.4	64
813	Monoclonal gammopathy of undetermined significance: a consensus statement. British Journal of Haematology, 2010, 150, 28-38.	1.2	95
814	High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients. British Journal of Haematology, 2010, 150, 587-591.	1.2	11
815	Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis. Journal of Clinical Oncology, 2010, 28, 1031-1037.	0.8	273
816	Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization. Clinical and Developmental Immunology, 2010, 2010, 1-15.	3.3	44
817	Survival Effect of Venous Thromboembolism in Patients With Multiple Myeloma Treated With Lenalidomide and High-Dose Dexamethasone. Journal of Clinical Oncology, 2010, 28, 132-135.	0.8	58
818	Smoldering (Asymptomatic) Multiple Myeloma: Current Diagnostic Criteria, New Predictors of Outcome, and Follow-Up Recommendations. Journal of Clinical Oncology, 2010, 28, 690-697.	0.8	101
819	Avascular Osteonecrosis of the Jaw as a Side Effect of Bisphosphonate Treatment. Onkologie, 2010, 33, 288-289.	1.1	10
820	Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective. Oncologist, 2010, 15, 6-25.	1.9	85
821	Clinical Characteristics and Outcome of Primary Systemic Light-Chain Amyloidosis in Greece. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 56-61.	0.2	16
822	Bortezomib as a Treatment Option in Patients With WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 110-117.	0.2	20
823	Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group. Journal of Clinical Oncology, 2010, 28, 4976-4984.	0.8	358
824	Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: A randomized placebo-controlled study. Atherosclerosis, 2010, 210, 194-198.	0.4	53
825	Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncology, The, 2010, 11, 1086-1095.	5.1	187
826	Intravenous pamidronate for myeloma bone disease: can the dose be lowered?. Lancet Oncology, The, 2010, 11, 913-914.	5.1	0
827	High dose melphalan in primary systemic amyloidosis: status quo?. Leukemia and Lymphoma, 2010, 51, 2149-2151.	0.6	0
828	Efficacy of methotrexate/vinblastine/doxorubicin/cisplatin combination in gemcitabine-pretreated patients with advanced urothelial cancer: a retrospective analysis. Open Access Journal of Urology, 2010, 2, 193.	0.3	4

#	Article	IF	Citations
829	Prostate Cancer with Metastasis to the Omentum and Massive Ascites: A Rare Manifestation of a Common Disease. Onkologie, 2009, 32, 758-761.	1.1	21
830	Pathogenesis and management of myeloma bone disease. Expert Review of Hematology, 2009, 2, 385-398.	1.0	45
831	First-line bortezomib benefits patients with multiple myeloma. Nature Reviews Clinical Oncology, 2009, 6, 683-685.	12.5	6
832	Update on Treatment Recommendations From the Fourth International Workshop on WaldenstrÃ¶m's Macroglobulinemia. Journal of Clinical Oncology, 2009, 27, 120-126.	0.8	207
833	Association between Transcriptional Activity, Local Chromatin Structure, and the Efficiencies of Both Subpathways of Nucleotide Excision Repair of Melphalan Adducts. Cancer Research, 2009, 69, 4424-4433.	0.4	23
834	VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study. Journal of Clinical Oncology, 2009, 27, 6086-6093.	0.8	154
835	Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. Haematologica, 2009, 94, 372-379.	1.7	60
836	Could Rigorous Diagnosis and Management of Hypertension Reduce Cardiac Events in Patients With Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors?. Journal of Clinical Oncology, 2009, 27, 2567-2569.	0.8	20
837	Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo. Journal of Cellular and Molecular Medicine, 2009, 13, 3929-3938.	1.6	27
838	Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. European Journal of Haematology, 2009, 82, 426-432.	1.1	104
839	Somatic mutations of adenomatous polyposis coli gene and nuclear bâ€catenin accumulation have prognostic significance in invasive urothelial carcinomas: Evidence for Wnt pathway implication. International Journal of Cancer, 2009, 124, 103-108.	2.3	57
840	Endovascular stenting for the management of port-a-cath associated superior vena cava syndrome. Emergency Radiology, 2009, 16, 143-146.	1.0	12
841	Anti-tumor immune response in ovarian cancer: clinical implications, prognostic significance and potential for novel treatment strategies. Oncology Reviews, 2009, 3, 173-186.	0.8	0
842	Targeted therapies in multiple myeloma. Targeted Oncology, 2009, 4, 23-36.	1.7	31
843	Periodic Therapeutic Plasma Exchange in Patients With Moderate to Severe Chronic Myasthenia Gravis Nonâ€Responsive to Immunosuppressive Agents: An Eight Year Followâ€Up. Therapeutic Apheresis and Dialysis, 2009, 13, 174-178.	0.4	19
844	Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Reviews, 2009, 23, 87-93.	2.8	35
845	Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma. Cancer Treatment Reviews, 2009, 35, 738-743.	3.4	9
846	Prognostication in Young and Old Patients with WaldenstrÃ¶m's Macroglobulinemia: Importance of the International Prognostic Scoring System and of Serum Lactate Dehydrogenase. Clinical Lymphoma and Myeloma, 2009, 9, 50-52.	1.4	28

#	Article	IF	Citations
847	Rituximab-Based Treatments in WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2009, 9, 59-61.	1.4	12
848	Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors. Clinical Lymphoma and Myeloma, 2009, 9, 302-306.	1.4	101
849	Dickkopf-1: a suitable target for the management of myeloma bone disease. Expert Opinion on Therapeutic Targets, 2009, 13, 839-848.	1.5	62
850	International prognostic scoring system for WaldenstrÃ¶m macroglobulinemia. Blood, 2009, 113, 4163-4170.	0.6	366
851	Treatment of Relapsed/Refractory Multiple Myeloma. Seminars in Hematology, 2009, 46, 143-157.	1.8	49
852	Multiple Myeloma in the Era of Novel Agents. Seminars in Hematology, 2009, 46, 107-109.	1.8	1
853	Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica, 2009, 94, 300-302.	1.7	70
854	Study of T Lymphocytes Infiltrating Peritoneal Metastases in Advanced Ovarian Cancer. International Journal of Gynecological Cancer, 2009, 19, 1329-1334.	1.2	31
855	Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. Thrombosis and Haemostasis, 2009, 101, 541-546.	1.8	19
856	Full Dose of Lenalidomide for 12 Months Followed by a Lower Maintenance Dose Improves Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma.. Blood, 2009, 114, 2874-2874.	0.6	4
857	Neutropenia Is a Predictable and Early Event in Affected Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide in Combination with Dexamethasone.. Blood, 2009, 114, 2879-2879.	0.6	7
858	Bortezomib Plus Melphalanâ€“Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalanâ€“Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.. Blood, 2009, 114, 3859-3859.	0.6	3
859	Lenalidomide plus Dexamethasone Has Similar Tolerability and Efficacy in Treatment of Relapsed/Refractory Multiple Myeloma Patients with or without History of Neuropathy.. Blood, 2009, 114, 3873-3873.	0.6	7
860	Primary Therapy of Waldnestrom's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network.. Blood, 2009, 114, 2886-2886.	0.6	0
861	Therapeutic Plasma Exchange Combined With Immunomodulating Agents in Secondary Progressive Multiple Sclerosis Patients. Therapeutic Apheresis and Dialysis, 2008, 12, 105-108.	0.4	7
862	Prognostic value of kallikreinâ€related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA). Cancer Science, 2008, 99, 2224-2229.	1.7	24
863	Prognostic and Predictive Factors in Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel and Estramustine: A Single Institution Experience. European Urology, 2008, 53, 323-332.	0.9	18
864	Editorial Comment on: New treatment approaches for prostate cancer based on peptide analogues. European Urology, 2008, 53, 899-900.	0.9	0

#	Article	IF	Citations
865	Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. New England Journal of Medicine, 2008, 359, 906-917.	13.9	1,787
866	Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood, 2008, 112, 4445-4451.	0.6	164
867	Wegenerâ€™s Granulomatosis Presenting as a Renal Mass. Urology, 2008, 71, 547.e1-547.e2.	0.5	20
868	Biweekly Doxorubicin/Ketoconazole as Second-Line Treatment in Docetaxel-Resistant, Hormone-Refractory Prostate Cancer. Urology, 2008, 71, 1181-1185.	0.5	2
869	Carboplatin and Paclitaxel versus Cisplatin, Paclitaxel and Doxorubicin for first-line chemotherapy of Advanced Ovarian Cancer: A Hellenic Cooperative Oncology Group (HeCOG) study. European Journal of Cancer, 2008, 44, 2169-2177.	1.3	19
870	Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncology, The, 2008, 9, 1166-1172.	5.1	131
871	Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leukemia and Lymphoma, 2008, 49, 890-895.	0.6	74
872	Thalidomide plus dexamethasone as primary therapy for newly diagnosed patients with multiple myeloma. Nature Clinical Practice Oncology, 2008, 5, 690-691.	4.3	6
873	Mantle-Cell Lymphoma (Multiple Lymphomatous Polyposis) of the Entire GI Tract. Journal of Clinical Oncology, 2008, 26, 1555-1557.	0.8	22
874	Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma. Journal of Clinical Oncology, 2008, 26, 5904-5909.	0.8	139
875	Mitogen-Activated Protein Kinase Activation in Lung Adenocarcinoma: A Comparative Study between Ever Smokers and Never Smokers. Clinical Cancer Research, 2008, 14, 4096-4102.	3.2	20
876	Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10â€‰549 patients from the International Myeloma Working Group. Blood, 2008, 111, 4039-4047.	0.6	190
877	High dose therapy for light chain amyloidosis: Can we reduce treatment related mortality further?. Leukemia and Lymphoma, 2008, 49, 4-5.	0.6	2
878	Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: Promising results in marginal zone lymphoma. Leukemia and Lymphoma, 2008, 49, 68-74.	0.6	13
879	The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens. Haematologica, 2008, 93, 1420-1422.	1.7	42
880	Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. Haematologica, 2008, 93, 451-454.	1.7	27
881	The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opinion on Pharmacotherapy, 2007, 8, 497-509.	0.9	46
882	Primary Treatment of WaldenstrÃ¶m Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide. Journal of Clinical Oncology, 2007, 25, 3344-3349.	0.8	264

#	Article	IF	Citations
883	Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica, 2007, 92, 546-549.	1.7	160
884	Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: Long term follow up and disease control after subsequent treatments. Leukemia and Lymphoma, 2007, 48, 754-758.	0.6	16
885	Biweekly Carboplatin/Gemcitabine in Patients with Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: Report of Efficacy, Quality of Life and Geriatric Assessment. Oncology, 2007, 73, 290-297.	0.9	46
886	Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 2007, 357, 2123-2132.	13.9	1,365
887	Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica, 2007, 92, 1351-1358.	1.7	179
888	Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. Haematologica, 2007, 92, 1505-1512.	1.7	33
889	Two Cycles of Etoposide/Cisplatin Cured All Patients with Stage I Testicular Seminoma: Risk-Adapted Protocol of the Hellenic Cooperative Oncology Group. Urology, 2007, 70, 1179-1183.	0.5	5
890	Management of Relapsed and Relapsed Refractory Myeloma. Hematology/Oncology Clinics of North America, 2007, 21, 1175-1215.	0.9	8
891	Laparoscopy in the evaluation of women with unexplained ascites: An invaluable diagnostic tool. Journal of Minimally Invasive Gynecology, 2007, 14, 43-48.	0.3	7
892	How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide. Leukemia and Lymphoma, 2007, 48, 2295-2297.	0.6	4
893	Thalidomide in the treatment of multiple myeloma. Best Practice and Research in Clinical Haematology, 2007, 20, 681-699.	0.7	17
894	Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. British Journal of Haematology, 2007, 137, 560-568.	1.2	37
895	Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynecologic Oncology, 2007, 104, 580-585.	0.6	28
896	Squamous Cell Esophageal Carcinoma as a Second Primary Malignancy in a Woman with Epithelial Ovarian Cancer. Digestive Diseases and Sciences, 2007, 52, 3099-3101.	1.1	0
897	Treatment of Waldenstromâ€™s Macroglobulinemia. Current Treatment Options in Oncology, 2007, 8, 144-153.	1.3	17
898	Treatment of Light Chain (AL) Amyloidosis and Light Chain Deposition Disease (LCDD) with the Combination of Bortezomib and Dexamethasone.. Blood, 2007, 110, 191-191.	0.6	1
899	Treatment of Patients with Multiple Myeloma Complicated by Renal Failure with Bortezomib - Based Regimens.. Blood, 2007, 110, 2739-2739.	0.6	2
900	The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio.. Blood, 2007, 110, 3596-3596.	0.6	2

#	Article	IF	Citations
901	Decreased Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZA) after Application of Preventive Measures.. Blood, 2007, 110, 3609-3609.	0.6	3
902	Thalidomide Based Regimens (TBR) for Relapsed/Refractory Multiple Myeloma Patients: Long Term Follow Up, Unmaintained Remissions and Disease Control after Subsequent Treatments.. Blood, 2007, 110, 4812-4812.	0.6	0
903	The International Prognostic Scoring System for Waldestromâ€™s Macroglobulinemia (ISSWM) Is Applicable in Patients Treated with Rituximab-Based Regimens.. Blood, 2007, 110, 3615-3615.	0.6	0
904	Symptomatic Waldenstromâ€™s Macroglobulinemia (WM) in Young Patients: Disease Characteristics and Outcome.. Blood, 2007, 110, 4730-4730.	0.6	0
905	High Bone Turnover and Increased Angiogenesis Cytokines in Patients with POEMS Syndrome.. Blood, 2007, 110, 3525-3525.	0.6	0
906	Macrofocal multiple myeloma in young patients: A distinct entity with favorable prognosis. Leukemia and Lymphoma, 2006, 47, 1553-1556.	0.6	30
907	Primary gastrointestinal non-Hodgkin's lymphoma: A clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leukemia and Lymphoma, 2006, 47, 2140-2146.	0.6	128
908	Extranodal non-Hodgkin's lymphoma presenting as an abdominal wall mass. A case report and review of the literature. Leukemia and Lymphoma, 2006, 47, 329-332.	0.6	10
909	Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy?. Leukemia and Lymphoma, 2006, 47, 2271-2272.	0.6	7
910	Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival. Breast Cancer Research and Treatment, 2006, 100, 161-167.	1.1	14
911	Update on Recommendations for Assessing Response from the Third International Workshop on WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2006, 6, 380-383.	1.4	107
912	Non-Hodgkin's Lymphoma of the Renal Pelvis. Clinical Lymphoma and Myeloma, 2006, 6, 404-406.	1.4	9
913	Prognostic Value of Serum Î²2-Microglobulin in Patients with WaldenstrÃ¶m's Macroglobulinemia Requiring Treatment. Clinical Lymphoma and Myeloma, 2006, 7, 205-209.	1.4	22
914	Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure. DNA Repair, 2006, 5, 972-985.	1.3	21
915	Concurrent development of testicular seminoma and choriocarcinoma of the superior mediastinum, presented as cervical mass: a case report and implications about pathogenesis of germ-cell tumours. BMC Clinical Pathology, 2006, 6, 8.	1.8	6
916	Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with doseâ€“dense sequential adjuvant chemotherapy. Breast Cancer Research and Treatment, 2006, 96, 251-261.	1.1	42
917	Advanced stage clear-cell epithelial ovarian cancer: The Hellenic cooperative oncology group experience. Gynecologic Oncology, 2006, 102, 285-291.	0.6	123
918	Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group. BMC Cancer, 2006, 6, 228.	1.1	11

#	Article	IF	Citations
919	The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. Cancer, 2006, 106, 297-303.	2.0	78
920	Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. International Journal of Cancer, 2006, 119, 1728-1731.	2.3	153
921	Young Age Is Associated with Favorable Characteristics but Is Not an Independent Prognostic Factor in Patients with Epithelial Ovarian Cancer: A Single Institution Experience. Oncology, 2006, 70, 265-272.	0.9	18
922	Evaluation of the Prognostic Value of Cellular Inhibitor of Apoptosis Protein in Epithelial Ovarian Cancer Using Automated Quantitative Protein Analysis. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1179-1183.	1.1	11
923	Current Treatment of Relapsed Ovarian Carcinoma. Current Cancer Therapy Reviews, 2006, 2, 211-221.	0.2	0
924	Rituximab therapy in monoclonal IgM-related neuropathies. Leukemia and Lymphoma, 2006, 47, 859-864.	0.6	51
925	Treatment of AL amyloidosis with high dose therapy and autologous stem cell transplantation. Leukemia and Lymphoma, 2006, 47, 963-964.	0.6	1
926	International Prognostic Scoring System (IPSS) for Waldenstroì^mâ€™s Macroglobulinemia (WM).. Blood, 2006, 108, 127-127.	0.6	23
927	The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1Î± and Angiogenic Cytokines.. Blood, 2006, 108, 3541-3541.	0.6	8
928	Deep Vein Thrombosis in Myeloma: Estimate of Prevelance and Recommendations for Therapy Based upon a Survey of Members of the International Myeloma Working Group (IMWG).. Blood, 2006, 108, 3571-3571.	0.6	2
929	Prognostic Significance of Magnetic Resonance Imaging (MRI) of Bone Marrow (BM) in Patients with Multiple Myeloma (MM) Undergoing Treatment with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplantation (ASCT).. Blood, 2006, 108, 3095-3095.	0.6	0
930	Diffuse MRI Pattern of Marrow Infiltration Correlates with Suppressed Bone Formation and Increased Incidence of Vertebral Fractures in Multiple Myeloma.. Blood, 2006, 108, 5018-5018.	0.6	0
931	Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica, 2006, 91, 968-71.	1.7	223
932	Bcl-2 protein and DNA ploidy in renal cell carcinoma: Do they affect patient prognosis?. International Journal of Urology, 2005, 12, 563-569.	0.5	10
933	Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group. European Journal of Haematology, 2005, 75, 124-129.	1.1	24
934	Multiple myeloma in elderly patients: prognostic factors and outcome. European Journal of Haematology, 2005, 75, 370-375.	1.1	48
935	Familial female and male germ cell cancer. A new syndrome?. Gynecologic Oncology, 2005, 96, 254-255.	0.6	13
936	Clinicopathological features of ovarian carcinosarcomas: a single institution experience. Gynecologic Oncology, 2005, 96, 136-142.	0.6	35

#	Article	IF	Citations
937	Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience. Gynecologic Oncology, 2005, 97, 436-441.	0.6	133
938	Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer, 2005, 103, 2629-2635.	2.0	58
939	Extent of Damage and Repair in the p53 Tumor-Suppressor Gene After Treatment of Myeloma Patients With High-Dose Melphalan and Autologous Blood Stem-Cell Transplantation Is Individualized and May Predict Clinical Outcome. Journal of Clinical Oncology, 2005, 23, 4381-4389.	0.8	23
940	Multifocal Extranodal Nonâ€Hodgkin Lymphoma: A Clinicopathologic Study of 37 Cases in Greece, a Hellenic Cooperative Oncology Group Study. Oncologist, 2005, 10, 734-738.	1.9	22
941	Subcellular Localization and Protein Levels of Cyclin-Dependent Kinase Inhibitor p27 Independently Predict for Survival in Epithelial Ovarian Cancer. Clinical Cancer Research, 2005, 11, 8384-8390.	3.2	35
942	Thalidomide and immunomodulatory drugs in the treatment of cancer. Expert Opinion on Investigational Drugs, 2005, 14, 45-55.	1.9	25
943	Neoadjuvant chemotherapy in invasive bladder cancer. Expert Review of Anticancer Therapy, 2005, 5, 993-1000.	1.1	2
944	Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer. Clinical Cancer Research, 2005, 11, 8637-8643.	3.2	127
945	Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors. Journal of Clinical Oncology, 2005, 23, 8580-8587.	0.8	990
946	WaldenstrÃ¶m's macroglobulinemia. Best Practice and Research in Clinical Haematology, 2005, 18, 747-765.	0.7	39
947	Diagnosis and Management of Waldenstrom's Macroglobulinemia. Journal of Clinical Oncology, 2005, 23, 1564-1577.	0.8	225
948	The Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma Who Receive Biphosphonates Depends on the Type of Biphosphonate.. Blood, 2005, 106, 637-637.	0.6	15
949	Discordant Response or Progression in Patients with Myeloma Treated with Thalidomide-based Regimens. Leukemia and Lymphoma, 2004, 45, 113-116.	0.6	28
950	Treatment of Relapsed/Refractory Multiple Myeloma with Thalidomide-based Regimens: Identification of Prognostic Factors. Leukemia and Lymphoma, 2004, 45, 2275-2279.	0.6	14
951	Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. The Hematology Journal, 2004, 5, 112-117.	2.0	129
952	Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). British Journal of Haematology, 2004, 126, 686-689.	1.2	93
953	Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecologic Oncology, 2004, 95, 695-700.	0.6	39
954	Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal protein. Annals of Hematology, 2004, 83, 658-60.	0.8	4

#	Article	IF	Citations
955	The International Staging System for Multiple Myeloma is Applicable in Symptomatic Waldenstrom's Macroglobulinemia. Leukemia and Lymphoma, 2004, 45, 1809-1813.	0.6	35
956	Treatment of Waldenstrom's Macroglobulinemia with Rituximab: Prognostic Factors for Response and Progression. Leukemia and Lymphoma, 2004, 45, 2057-2061.	0.6	39
957	Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study. Urology, 2004, 63, 120-125.	0.5	36
958	Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology, 2004, 64, 479-484.	0.5	108
959	Adverse effects of thalidomide administration in patients with neoplastic diseases. American Journal of Medicine, 2004, 117, 508-515.	0.6	122
960	Primary Mediastinal Large B-Cell Lymphoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 312-316.	0.6	7
961	Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Anti-Cancer Drugs, 2004, 15, 479-487.	0.7	5
962	Treatment of Multiple Myeloma. , 2004, , 137-157.		0
963	2-chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Seminars in Oncology, 2003, 30, 243-247.	0.8	106
964	Defining Waldenstrom's macroglobulinemia. Seminars in Oncology, 2003, 30, 107-109.	0.8	21
965	Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 110-115.	0.8	841
966	Expansion of CD8+ T cells that express low levels of the B cell-specific molecule CD20 in patients with multiple myeloma. British Journal of Haematology, 2003, 120, 478-481.	1.2	8
967	Treatment of Waldenstrom's Macroglobulinemia with the Combination of Fludarabine and Cyclophosphamide. Leukemia and Lymphoma, 2003, 44, 993-996.	0.6	56
968	Angiogenesis in human cancer: implications in cancer therapy. European Journal of Internal Medicine, 2003, 14, 459-469.	1.0	42
969	High Dose Therapy with Autologous Stem Cell Transplantation for Solitary Bone Plasmacytoma Complicated by Local Relapse or Isolated Distant Recurrence. Leukemia and Lymphoma, 2003, 44, 153-155.	0.6	11
970	Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives. Journal of Clinical Oncology, 2003, 21, 4444-4454.	0.8	113
971	Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma. The Hematology Journal, 2003, 4, 110-115.	2.0	13
972	Primary Treatment of Low-grade Non-Hodgkin's Lymphoma with the Combination of Fludarabine and Mitoxantrone: A Phase II Study of the Hellenic Cooperative Oncology Group. Leukemia and Lymphoma, 2002, 43, 111-114.	0.6	12

#	Article	IF	Citations
973	A Phase III Study of 5-Fluorouracil Versus 5-Fluorouracil Plus Interferon Alpha 2b Versus 5-Fluorouracil Plus Leucovorin in Patients With Advanced Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 23-30.	0.6	9
974	Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Nonâ€“Small-Cell Lung Cancer: A Phase III Randomized Trial. Journal of Clinical Oncology, 2002, 20, 3578-3585.	0.8	241
975	Treatment of WaldenstrÃ¶mâ€™s Macroglobulinemia With Rituximab. Journal of Clinical Oncology, 2002, 20, 2327-2333.	0.8	248
976	Extended Rituximab Therapy for Previously Untreated Patients with WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2002, 3, 163-166.	2.1	71
977	A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin. Cancer, 2002, 94, 452-458.	2.0	64
978	Combination of Ifosfamide, Paclitaxel, and Cisplatin for the Treatment of Metastatic and Recurrent Carcinoma of the Uterine Cervix: A Phase II Study of the Hellenic Cooperative Oncology Group. Gynecologic Oncology, 2002, 85, 476-482.	0.6	32
979	Light chain deposition disease of the liver without renal involvement in a patient with multiple myeloma related to liver failure and rapid fatal outcome. Digestive Diseases and Sciences, 2002, 47, 730-734.	1.1	33
980	Treatment of Waldenstromâ€™s Macroglobulinemia With Thalidomide. Journal of Clinical Oncology, 2001, 19, 3596-3601.	0.8	123
981	Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in Stage III and IV ovarian carcinoma. Cancer, 2000, 89, 1547-1554.	2.0	18
982	Non-cryopreserved peripheral blood progenitor cells collected by a single very large-volume leukapheresis: A simplified and effective procedure for support of high-dose chemotherapy. Journal of Clinical Apheresis, 2000, 15, 236-241.	0.7	12
983	Paclitaxel and Cisplatin in Advanced or Recurrent Carcinoma of the Endometrium: Long-Term Results of a Phase II Multicenter Study. Gynecologic Oncology, 2000, 78, 52-57.	0.6	81
984	Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood, 2000, 96, 2037-2044.	0.6	334
985	Successful Conservative Treatment of Neutropenic Enterocolitis Complicating Taxane-Based Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2000, 23, 309-313.	0.6	55
986	Treatment of Pancreatic Cancer With Docetaxel and Granulocyte Colony-Stimulating Factor: A Multicenter Phase II Study. Journal of Clinical Oncology, 1999, 17, 1779-1779.	0.8	79
987	Outpatient Treatment of Neutropenic Fever with Oral Antibiotics and Granulocyte Colony-Stimulating Factor. Oncology, 1999, 57, 127-130.	0.9	23
988	Hodgkinâ€™s disease with lymphocyte predominance: long-term results based on current histopathologic criteria. International Journal of Radiation Oncology Biology Physics, 1999, 43, 329-334.	0.4	17
989	MR imaging of complex tail-gut cysts. Clinical Radiology, 1999, 54, 118-122.	0.5	39
990	WALDENSTRÃ–M'S MACROGLOBULINEMIA. Hematology/Oncology Clinics of North America, 1999, 13, 1351-1366.	0.9	43

#	Article	IF	Citations
991	Bone Lesions with Soft-Tissue Mass: Magnetic Resonance Imaging Diagnosis of Lymphomatous Involvement of the Bone Marrow Versus Multiple Myeloma and Bone Metastases. Leukemia and Lymphoma, 1999, 34, 179-184.	0.6	34
992	Prognostic value of cytogenetics in multiple myeloma. British Journal of Haematology, 1998, 101, 189-194.	1.2	107
993	The prevalence of bcl-2, p53, and ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Human Pathology, 1998, 29, 146-154.	1.1	107
994	Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel. Urology, 1998, 52, 56-60.	0.5	50
995	Sequential Administration of Doxorubicin and Paclitaxel Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil Combination (CMF) in Women with Metastatic Breast Cancer. Oncology, 1998, 55, 533-537.	0.9	2
996	Very Late Relapse of Hodgkin's Disease After 24 Years of Complete Remission. Leukemia and Lymphoma, 1997, 28, 215-217.	0.6	2
997	Treatment of Langerhans Cell Histiocytosis with 2 Chlorodeoxyadenosine. Leukemia and Lymphoma, 1997, 25, 187-189.	0.6	24
998	Cisplatin, Ifosfamide, Methotrexate and Vinblastine Combination Chemotherapy for Metastatic Urothelial Cancer. Journal of Urology, 1997, 158, 408-411.	0.2	13
999	Late relapse of nonseminomatous germ cell tumor of the testis: Successful treatment with salvage chemotherapy alone. Urology, 1997, 49, 469-470.	0.5	5
1000	Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology, 1997, 50, 754-758.	0.5	78
1001	Primary Ovarian Non-Hodgkin's Lymphoma: Outcome after Treatment with Combination Chemotherapy. Gynecologic Oncology, 1997, 64, 446-450.	0.6	111
1002	Antimyosin Scintigraphy for Detection of Cardiac Amyloidosis. American Journal of Cardiology, 1997, 80, 963-965.	0.7	13
1003	A Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix. Cancer, 1997, 79, 2391-2395.	2.0	25
1004	Prunart Renal Lymphoma: A Clinical and Radiological Study. Journal of Urology, 1996, 155, 1865-1867.	0.2	46
1005	Myeloablative therapy for primary resistant multiple myeloma. Stem Cells, 1996, 13, 118-121.	1.4	10
1006	Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma. New England Journal of Medicine, 1996, 334, 488-493.	13.9	1,030
1007	9Complications and supportive therapy of multiple myeloma. Best Practice and Research: Clinical Haematology, 1995, 8, 845-852.	1.1	4
1008	Dosing of thioTEPA for myeloablative therapy. Cancer Chemotherapy and Pharmacology, 1995, 37, 155-160.	1.1	30

#	Article	IF	Citations
1009	VAD-Cyclosporine Therapy for VAD-Resistant Multiple Myeloma. Leukemia and Lymphoma, 1995, 19, 159-163.	0.6	8
1010	WaldenstrÃ¶m Macroglobulinemia Presenting as a Renal or Perirenal Mass: Clinical and Radiographic Features. Leukemia and Lymphoma, 1995, 17, 331-334.	0.6	23
1011	Rising Serum Lactate Dehydrogenase Often Caused by Granulocyte-or Granulocyte-Macrophage Colony Stimulating Factor and not Tumor Progression in Patients with Lymphoma or Myeloma. Leukemia and Lymphoma, 1995, 17, 473-477.	0.6	20
1012	Primary Lymphoma of the Prostate: Good Outcome with Doxorubicin-Based Combination Chemotherapy. Journal of Urology, 1995, 153, 1852-1854.	0.2	86
1013	Intensive Sequential Therapy for VAD-Resistant Multiple Myeloma. Leukemia and Lymphoma, 1994, 13, 479-484.	0.6	5
1014	The Treatment of Multiple Myeloma. New England Journal of Medicine, 1994, 330, 484-489.	13.9	376
1015	Allogeneic bone marrow transplantation for leukemia following piperazinedione and fractionated total body irradiation. American Journal of Hematology, 1994, 46, 82-86.	2.0	7
1016	The Expanding Role of Fludarabine in Hematologic Malignancies. Leukemia and Lymphoma, 1994, 14, 11-16.	0.6	26
1017	Primary treatment with 2-chiorodeoxyadenosine of low grade lymphomas that produce igg or IgA immunoglobulin. American Journal of Hematology, 1993, 43, 326-327.	2.0	3
1018	Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma. British Journal of Haematology, 1993, 83, 240-244.	1.2	36
1019	Risk of disease progression in asymptomatic multiple myeloma. American Journal of Medicine, 1993, 94, 57-61.	0.6	148
1020	Fludarabine therapy in WaldenstrÃ¶m's macroglobulinemia. American Journal of Medicine, 1993, 95, 49-52.	0.6	116
1021	Irreversibility of drug resistance in VAD-refractory myeloma. American Journal of Hematology, 1992, 40, 154-155.	2.0	0
1022	Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation. American Journal of Hematology, 1992, 41, 40-44.	2.0	17
1023	Paraneoplastic Cushing's syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer. Cancer, 1992, 69, 66-71.	2.0	80
1024	Breast cancer and second primary ovarian cancer in dermatomyositis. Gynecologic Oncology, 1991, 43, 286-290.	0.6	15
1025	An effective acute graft-vs.-host disease prophylaxis with minidose methotrexate, cyclosporine, and single-dose methylprednisolone. American Journal of Hematology, 1991, 38, 288-292.	2.0	8
1026	Prophylaxis of cytomegalovirus infection with ganciclovir in allogeneic marrow transplantation. European Journal of Haematology, 1991, 47, 371-376.	1.1	23

#	Article	IF	Citations
1027	DIAGNOSIS, RISK-STRATIFICATION, AND MANAGEMENT OF SOLITARY PLASMACYTOMA. , 0, , 150-163.		0
1028	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma. , 0, , 121-133.		2